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The recent increase in multidrug-resistant pathogens and associated morbidity/mortality 
demonstrate the immediate need for new antibiotic backbones with novel mechanisms of action. 
While natural products are a well-studied source of biologically active small molecules, peptidyl 
factors contributing to their medicinal properties remain largely unexplored. To expedite the 
search for this exciting class of compounds this dissertation describes the development, 
validation, and applications of PepSAVI-MS (Statistically-guided bioactive peptides prioritized 
via mass spectrometry). This highly versatile pipeline employs whole-cell bioactivity screening 
coupled with mass spectrometry and bioinformatics to identify bioactive peptides from complex 
biological extracts (Chapter 2). The development and validation of PepSAVI-MS was originally 
described using a botanical source through the successful detection and identification of a known 
antimicrobial peptide, cycloviolacin O2 (cyO2), from Viola odorata (Chapter 3). In addition to 
pipeline validation, this study widened the known antimicrobial spectrum for V. odorata 
cyclotides, establishing antibacterial activity of cyO2 against Acinetobacter baumannii, and 
explored novel anticancer activities for cycloviolacins by their cytotoxicity against ovarian, 
breast and prostate cancer cell lines.  
To demonstrate the versatility and wide applicability of PepSAVI-MS, validation studies 





experimental modifications to highlight pipeline utility. Identification of the virally-encoded 
antifungal killer toxin KP4 from Ustilago maydis P4 and the bacteriocin Bac-21 from 
Enterococcus faecalis pPD1 demonstrates proof-of-principle for bioactive peptide discovery 
from bacterial and fungal secretomes.  
Using the validated pipeline, a variety of natural product sources are probed to prioritize 
highly active species for downstream analysis. The plant species Amaranthus tricolor is 
presented as an example of novel antimicrobial activity identified with PepSAVI-MS (Chapter 
6). As demonstrated herein, the developed pipeline is powerful and highly versatile; PepSAVI-
MS can incorporate material from a variety of natural product sources and is able to 
accommodate any developed bioactivity screen. The flexible nature of this pipeline presents a 
valuable tool for diverse natural product exploration, and has the potential to lead to the 
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1.1 The Threat of Antimicrobial Resistance 
Antimicrobial resistance (AMR) is present in every country worldwide and has a direct impact 
on global health and economy. Human fatalities associated with antimicrobial resistance are 
estimated at 10 million per year worldwide and health-related economic losses are estimated to 
approach an ~3% decrease in gross domestic product exceeding $100 trillion by 20501. Treating 
common bacterial and fungal infections is becoming increasingly challenging as new resistance 
mechanisms develop and current methods are accelerated by the misuse of antimicrobial drugs1.  
Despite notable success of antibiotics in the past 70 years, bacterial diseases remain a leading 
cause of mortality worldwide, killing over 17 million people each year2-8. In the US, there are 
two million hospital acquired infections each year, resulting in ~100,000 deaths9. Almost a 
quarter of this number is caused by organisms for which there are no treatment options 
remaining10. Specifically, the emergence of antibiotic resistance in ESKAPE (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter species) pathogens has led to a significant increase 
in difficult-to-treat nosocomial infections with associated increases in morbidity/mortality. With 
many bacteria now unresponsive to conventional therapeutics and the anticipated trend toward 
increasing broad-spectrum resistance by 2030, there is an undeniable and desperate need to 
develop new antimicrobial therapeutics. 
Antimicrobial illness and resulting deaths are not only caused by bacteria, but fungi as well. 





fungal infections are largely treatable in healthy patients, infections in immunocompromised 
patients are often deadly. The Global Action Fund for Fungal Infections (GAFFI) reports that 
150 people die every hour from fungal infections worldwide, and that these infections reach over 
80% of the global population. In addition to this burden on the global population, fungal 
pathogens are one of the leading causes of agricultural crop loss, accounting for >12% of annual 
crop loss worldwide11. Among the most common and relevant agricultural fungal pathogens are 
Fusarium sp., responsible for Fusarium Head Blight in wheat and barley12, and Ustilago maydis, 
responsible for corn smut virus13. With the threat of both bacterial and fungal pathogens, it 
becomes imperative that new methods and innovative technologies are employed to replenish our 
dwindling arsenal of antimicrobial drugs.  
1.2 The Scarcity of the Drug Discovery Pipeline 
While >100 antibacterial agents have been developed to treat human disease since the 
discovery of sulfonamides, our current therapeutic options are worse now than at almost any 
time since the discovery of antibiotics14. Current methods for antibiotic drug discovery are being 
outpaced by the rise of antimicrobial resistance8, and the recent detection of plasmid-borne mcr-1 
mediated colistin resistance in E. coli within the United States further emphasizes the dire need 
for antimicrobial discovery with novel mechanisms of action15.  
Successful drug development reaching commercialization over the last fifty years has largely 
focused on the discovery of natural antibiotic compounds followed by incremental changes to 
chemical structure of these backbones16. Advances in large-scale genome sequencing was 
predicted to herald an era of genes-to-drugs, where specific bacterial targets would be identified 
and a small molecule inhibitor would be found through screening of large chemical libraries to 





bacterial physiology to be more complex than anticipated, with many genes having unknown 
functions. Characterized pathways are extraordinarily complex, contain redundancy, and/or have 
the capacity to rapidly develop resistance to new compounds. Also, unanticipated challenges 
have arisen in the search for appropriate targets for small molecule inhibitors3. This is further 
complicated by difficulties associated with bacterial cell wall and membrane permeability 
relative to host bioavailability3. Attempts to target a specific, isolated gene product fail to 
identify compounds that have the physiological capacity to inhibit growth of, or kill, intact cells. 
Attempts at using whole cell screening assays are not high throughput as they test individual 
compounds against a bacterial, fungal, or cancer cell culture. As a consequence, large 
pharmaceutical companies have retreated from antibiotic research and smaller biotech companies 
that are still pursuing this research are returning to low efficiency natural product isolation. A 
highly efficient screening pipeline that tests antibiotic-like compounds in complex mixtures 
against growing bacterial cells is needed to overcome the difficulties seen with the current 
discovery pipelines3, 16-17. 
1.3 Peptides as Drugs 
The push for alternative strategies to increase identification of novel lead compounds has 
contributed to increased interest in the development of peptides as drug candidates. Peptide-
based therapeutics boast higher selectivity than small molecules and offer better tissue 
penetration and lower manufacturing costs than proteins18. While peptides were considered as 
potential therapeutics without success many years ago, increasing prevalence of antibiotic 
resistance and the steady entry into the “post-antibiotic era” encourage reconsideration of this 
class of compounds. In fact, several peptide antibiotics (i.e. polymyxin B, colistin, daptomycin) 





Antibiotics that should be treated as options of “last resort” when all alternatives have failed in 
order to preserve their effectiveness19. Recent advances in peptide modification, formulation, and 
delivery methods can address known limitations18, including modification of peptide 
length/content to increase selectivity20-23, stapling and/or peptidomimetic conversion techniques 
to improve pharmacokinetic properties24-26, incorporating active peptides into stable scaffolds 
capable of oral delivery methods27, and encapsulation to protect from metabolic degradation or 
allow for tissue-specific release23, 28. A recent study reported that stapling of the myeloid cell 
leukemia 1 (Mcl-1) protein not only increased stability of the α-helical structure but also 
increased target binding affinity and specificity for Mcl-1 over related Bcl-2 proteins, further 
highlighting the potential of this class of compounds29. Bioactive peptides also hold great 
potential in combination therapy-based applications as their cell penetration mechanism both 
initiate cell death and allow for increased penetration of drugs with intracellular targets. The 
advantages offered by peptide-based drugs have led to the recent approval and additional 
development of a number of compounds, with approximately 140 peptide-based compounds 
currently in clinical trials and an estimated 500-600 additional drugs in development18,30.  
1.4 Natural Products as a Source of Novel Lead Compounds  
Natural products play a pivotal role in drug discovery yet remain a largely untapped resource. 
Plant- and microbial-based natural products have long been sources for lead compounds and 
inspiration for new chemistries at the forefront of drug discovery31-38.  
Plant-based natural products have been relied upon for centuries for primary health care in 
developing nations and have contributed substantially to Western medicine. While tens of 
thousands of plant species are estimated to be used traditionally, only a small percentage have 





mammals, plants rely on a complex innate immune response for protection against invading 
fungal and bacterial pathogens41, including secretion of peptide “danger signals” with broad- 
spectrum antimicrobial properties42-46. Despite hundreds of millions of years of antimicrobial 
peptide (AMP)-modulated host-pathogen interactions, antimicrobial resistance to continually 
evolving plant AMPs has seldom been seen in nature, demonstrating the adaptability and 
efficacy of these defense molecules47.  
The primary and tertiary structures of known AMPs are highly diverse- however, most are 
<10 kDa and require a net positive charge and intact disulfide bridges for bioactivity. Significant 
variations in tertiary structure have led to the classification of seven different plant AMP families 
(cyclotides, thionin, snakin, defensin, knottin, hevein-like and lipid-transfer; Figure 1.1), all of 
which are involved in innate pathogen defense48-49. Of the six kingdoms represented in the 
antimicrobial peptide database, plants represent the second most prevalent source of AMPs 
(behind animals)50.  
From the discovery of the first plant AMP over 45 years ago, a purothionin in wheat flour 
(Triticum aestivum) with gram-positive antibacterial activity, AMPs have been isolated from 
virtually every plant tissue (seeds, roots, stems, leaves, and flowers) and from a variety of 
botanical species as diverse as grain crops, hellebores, tobacco, euphorbias, violets, coffee, and 
Arabidopsis thaliana45, 49, 51-52. Snakins (i.e. Snakin-1 from Solanum tuberosum and Snakin-2 
from Solanum lycopersicum) are six intramolecular disulfide-containing AMPs that exhibit 
broad-spectrum activity against bacteria and fungi in low micromolar concentrations53-54. Plant 
defensins are ubiquitous in the plant kingdom and analogous to defensins found in animals, 
fungi, and insects. They display potent insecticidal, antifungal, and antibacterial activities likely 





α-amylases and proteases in target cells, electrostatic and amphipathic membrane interactions, 
and ion channel blocking55. Cyclotides and knottin-like peptides (i.e. cycloviolacins 1-25 from 
Viola sp.) are structurally robust molecules, containing three interlocking disulfides, with high 
levels of antifungal, insecticidal and antibacterial activities56. Despite this impressive display, the 
plant kingdom as a whole has barely been tapped with respect to depth of AMP discovery within 
a given species or across the >300,000 known plant species. As such, plants remain a rich 
reserve of uncharted bioactive peptides. 
While lacking the complexity of the plant immune system, microbes produce a wide variety 
of defense molecules to leverage competitive advantage over invading microbial pathogens. Both 
bacteria and fungi have developed intricate systems to for environmental protection, including 
the production of bacteriocins in bacteria57 and the establishment of symbiotic relationships with 
viruses in fungi13. Although created for survival, the innate bioactivity of these peptides poses a 
promising source of molecules to exploit for drug discovery, agriculture, and food safety 
applications58-59. The antimicrobial peptide, copsin, from the basidiomycete Coprinopsis cinerea, 
was first discovered in 2014 and has potent activity against gram-positive bacteria including both 
the human pathogen Enterococcus faecium and the foodborne pathogen Listeria 
monocytogenes60. Additionally, there has been a growing interest in the agricultural use of 
bioactive peptides for crop protection, including transgenic expression in plants and topical 
application as biopesticides. Spear-T, a bioinsecticide derived from spider venom and marketed 
by Vestaron, has recently been approved by the EPA for commercial use. Importantly, unlike 
many currently used neonicotinoid-containing products, Spear-T has no adverse effects on bees 
or other beneficial insects, highlighting additional benefits of certain peptide-based agricultural 





food safety applications, including the use of bacteriocins from lactic acid bacteria as starter 
cultures in food fermentation62. 
1.5 Current Methods for the Discovery of Bioactive Peptides 
Traditional proteomics/peptidomics profiling aims to identify and characterize all peptide and 
protein constituents in an organism. While essential for in-depth understanding of an organism, 
targeted methods to identify peptidyl constituents are necessary to facilitate rapid bioactive 
peptide discovery. Common approaches for targeted bioactive peptide identification include 
bioassay-guided fractionation and genome mining.  
1.5.1 Bioassay Guided Fractionation 
Bioassay-guided fractionation approaches employ iterative rounds of fractionation, 
bioactivity screening, and LC-MS analysis to isolate a single bioactive compound (Figure 1.2). 
Fractions typically undergo 3+ rounds of fractionation to isolate the activity to a single 
compound, with each iterative round of fractionation resulting in loss of material and 
inefficiency of process. As such, this approach is labor intensive and displays an innate bias 
towards highly active and abundant compounds, often resulting in isolation and re-identification 
of already known compounds63-67. However, bioassay guided fractionation has served as the gold 
standard for bioactive compound discovery as it is simplistic in nature, provides a direct measure 
of bioactivity, and is amenable to any developed bioassay. 
1.5.2 Genome Mining 
Alternatively, genome mining can be used to predict novel bioactive peptides in a given 
sequenced organism (Figure 1.3)68. Genomic prediction relies on a strong knowledgebase of 
known bioactive peptide sequences, processing enzymes, and biosynthetic pathways to 





Pep2Path69, RiPPquest70, and NRPquest71) have been developed to assist in identifying target 
biosynthetic gene clusters. Once identified, biosynthetic gene clusters capable of producing 
bioactive peptides can be cloned and expressed in a host organism to allow for access to 
bioactive peptides that are not constitutively expressed in a given organism. Although this 
approach makes previously inaccessible peptide products now accessible, it requires a strong 
training data set of known bioactive peptide biosynthetic pathways. While highly useful in 
bacterial species, these systems are less developed in complex organisms including plants. 
Furthermore, this approach has no direct measure of bioactivity and requires extensive follow-up 
experiments for activity validation. Low throughput, replication of known compounds, and 
inefficiency of process result in either case65, 72-73.  
1.6 The PepSAVI-MS Pipeline 
To expedite the search for natural product bioactive peptides, the PepSAVI-MS pipeline has 
been developed (Chapter 2). Relying on a multi-pronged approach, the PepSAVI-MS pipeline 
utilizes selective extraction and fractionation of peptide source material, bioactivity screening, 
and statistics-guided mass spectrometry-based peptidomics for the targeted identification and 
characterization of only putative bioactive compounds. The initial development and validation of 
PepSAVI-MS is described using a botanical source through the successful detection and 
identification of a known antimicrobial peptide, cycloviolacin O2 (cyO2), from Viola odorata 
(Chapter 3). To demonstrate the versatility and wide applicability of PepSAVI-MS, validation 
studies were performed using fungal (Chapter 4) and bacterial sources (Chapter 5), with optional 
experimental modifications to highlight pipeline utility. Identification of the virally-encoded 
antifungal killer toxin KP4 from Ustilago maydis P4 and the bacteriocin Bac-21 from 





from bacterial and fungal secretomes. Using the validated pipeline, a variety of natural product 
sources are probed to prioritize highly active species for downstream analysis. The plant species 
Amaranthus tricolor is presented as an example of novel antimicrobial activity identified with 
PepSAVI-MS (Chapter 6). 
In comparison to current bioactive peptide discovery methods, PepSAVI-MS boasts 
increased speed of identification by requiring minimal fractionation while maintaining a direct 
measure of activity. PepSAVI-MS does not require a priori knowledge of an organisms’ genome 
or known biosynthetic clusters that produce bioactive peptides. Furthermore, there is no inherent 
bias towards highly active or abundant compounds. Together, these unique aspects of PepSAVI-
MS allow for the high-throughput exploration of a suite of natural products with the opportunity 









Figure 1.1 Plant antimicrobial peptide families. Representative structures gathered from the 
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 Detailed PepSAVI-MS Protocols  
2.1 Introduction 
PepSAVI-MS is a streamlined pipeline to facilitate natural product bioactive peptide 
discovery and consists of the following major steps: plant or microbial growth and harvesting, 
peptide extraction, peptide library generation, bioactivity screening, LC-MS/MS, and statistical 
analysis to identify bioactive components. While previous experiments in the Hicks Laboratory 
influenced many of the techniques and procedures described in this chapter, all of the protocols 
required modification for use in PepSAVI-MS. As such, this chapter serves as detailed reference 
manual for the techniques laying the foundation of PepSAVI-MS. The protocols discussed below 
serve as a starting point for new experiments, but may require adjustments or optimization for 
each individual species, bioactivity assay, or available LC-MS platform.  
2.2 Plant Growth and Harvesting 
Plant species are selected based on criteria including known antimicrobial bioactivity, 
traditional medicinal properties, and availability. Seeds or seedlings are obtained through 
commercial sources (e.g. Horizon Herbs, Southern Exposure Seed Exchange) that carry out 
rigorous testing to ensure correct identity of seeds, plants, and roots. Upon arrival, seeds are 
stored at room temperature in original packaging until planted in the UNC Greenhouse Facility. 
The greenhouse is kept between 63.5 and 68.5°F and is on a 14-hour daylight cycle. Seeds of 
each species are planted in the appropriate soil for optimal growth conditions and are allowed to 
grow until ample tissue is available (~6-10 weeks). For species that are difficult to germinate, a 





solution is to order the live plant, if available, and transplant into standard greenhouse 
soil/conditions. If this option is used (e.g. Viola odorata), the live plant should be kept alive as 
long as possible to ensure sufficient collection of aerial tissue. Other methods to increase 
germination include shocking or scratching the seed coat, addition of gibberellic acid to the soil, 
or growth in a greenhouse chamber with optimized temperature and humidity conditions (see the 
notebook “Danny Lee 2016-2017/Wilaysha Evans” for specific growth conditions for each 
species). These methods have been used with varying degrees of success and require research of 
optimal growth conditions of each individual species before use. Regardless of growth strategy, 
healthy aerial tissue, excluding stem mass if possible, is transferred to aluminum packets, flash 
frozen under liquid nitrogen, and stored at -80°C to preserve protein structure and function. 
2.3 Peptide Extraction  
Nearly all known AMPs have four important and relatively conserved physical properties: 
they are cysteine rich, highly basic, amphipathic, and <10 kDa in size1. Current extraction 
protocols exploit these properties to selectively extract for bioactive peptide-like molecules: 1) 
aqueous buffers are used to selectively extract highly basic compounds and 2) size exclusion 
steps are used to select for the mass range of known bioactive peptides. Extraction protocols for 
two classes of natural products (plants and microbes) have been developed. All methods for 
peptide extraction result in the creation of a crude extract, which is used as the starting material 
for peptide library creation.  
2.3.1 Plants 
Frozen plant tissue is ground and extracted into aqueous buffer. Size exclusion steps via 
dialysis and molecular weight cutoff filters are used to select for the mass range of bioactive 





volume for preparation of crude extracts, which are stored at -80°C until further processing. The 
full protocol takes ~4 days to complete and is detailed as follows: 
Day 1: 
1. Estimate the tissue mass of the extraction species. Optimal extraction conditions use 100 
g of ground starting material and volumes listed below correspond to this weight. If less 
tissue is available, scale all reagents accordingly. 
2. Prepare 300 mL of acetic acid extraction buffer using the following recipe: 
a. 10% acetic acid (30 mL), 90% water (270 mL).  
b. Add 6 Roche EDTA-free protease inhibitor cocktail tablets. 
c. Add pepstatin (0.5 mg/mL stock, in 80% ethanol) to a final concentration of 1 
mg/L.  
d. Stir solution containing acetic acid, water, and protease inhibitors until plant 
tissue is ground. 
e. Right before addition of ground material, add 3% polyvinylpolypyrrolidone 
(PVPP) (g/mL). PVPP is insoluble in aqueous solution and will make the solution 
appear milky. 
3. Pre-chill the mortar in a nest of dry ice, covered in aluminum foil. Keep mortar in dry ice 
while grinding tissue. 
4. Add liquid nitrogen (N2(l)) to empty mortar, add batch of plant tissue and add more N2(l). 
5. Grind tissue until pulverized to a fine powder. Add N2 (l) as needed so that plant material 





6. Allow liquid nitrogen to boil off and add pulverized batch to weigh boat. Continue to 
grind until this weight reaches 100 g. If storing ground tissue in the weigh boat while 
continuing to grind, be sure to store ground tissue at -80℃. 
7. Once 100 g ground material is accumulated, immediately add the PVPP and then plant 
material to the beaker with extraction buffer and stir for 15 minutes at room temperature. 
8. Transfer beaker to 4℃ and stir for 4 h. 
9. Transfer extract into centrifuge bottles and centrifuge for 45 minutes at 13,200 RCF, 4°C. 
10. Gently remove bottles after centrifugation to avoid disturbing the insoluble pellet and 
pour supernatant into the top portion of a Stericup (Millipore, 0.45 μm, HV Durapore 
Membrane). 
11. Vacuum filter the liquid material through the Stericup. This process is highly variable 
depending on the plant species – can take anywhere from 5 minutes to multiple days to 
pull material through. Keep extract cold and on ice if this process is on the day(s) 
timescale. 
12. Store the filtered extract at 4℃ overnight. 
Day 2:  
13. Prepare Amicon Ultra-15 Centrifugal Filter Devices, 30000 MWCO (Millipore, 
UFC9010024) per manufacturer protocol to remove glycerin. Each filter holds 15 mL of 
extract and can be used twice for the same extract (estimate volume in Stericup and 
calculate accordingly). 





15. Centrifuge for 1 hour, at 3,220 RCF, 4°C. Check to see if the majority of the extract has 
gone through the filter.  If so, remove and save the bottom portion and add another round 
of extract to the top of the filter and repeat.  If not, continue with the centrifugation until 
most of the material is pulled through and then repeat. 
16. Recombine the filtrate into one container and save high-MW material for later analysis 
(store at -80°C). 
17. Pipette 5 mL of filtrate into 8 mL plastic tubes until all filtrate is used. Freeze at -20℃. 
Day 2 Overnight into Day 3: 
18. Once frozen, concentrate the material via vacuum centrifugation with no heat for 4-12 
hours depending on volume of extract. Do not concentrate to dryness, as this may lead to 
precipitation. 
19. At completion, note the volume. Expect a 10-fold concentration (~30 mL remaining). 
Day 3: 
20. Prepare SpectraPor Float-A-Lyzer G2 500-1000 MWCO 10 mL devices (G235051 
according to manufacturer instruction (wash with dilute ethanol, then water). 
21. During the conditioning step, prepare one 4 L Nalgene bucket of 5 mM ammonium 
formate (HPLC or MS Grade; Fluka 17843/70221). 
22. Adjust the buffer pH to 2.7 using formic acid. 
23. Dialyze concentrated extract into 5 mM ammonium formate, pH 2.7 using four 
preconditioned devices (~10 mL/device). 
24. Perform two dialysis steps, changing out the buffer in between; first dialysis for 4-6 h, 






25. Carefully remove the dialysis tubes from the buckets and draw out remaining liquid using 
long plastic dropper pipettes. 
26. Put approximately 5 mL dialyzed material into 8 mL plastic tubes and freeze at -20℃. 
27. Vacuum concentrate material following dialysis, with no heat, for 4-12 hours depending 
on volume of extract. Pool material into 2 mL micro centrifuge tubes as the process 
progresses. Do not concentrate to dryness, as this may lead to precipitation. 
28. Concentrate extract from 100 g of starting material (300 mL extraction buffer) down to 4 
mL final volume. This concentration is what we are calling the “1X” concentration. 
29. Aliquot into 420 μL portions and store at -80℃ until further use. 
2.3.2 Microbial Secretomes 
Modifications to the extraction protocol are required to capture microbial bioactive peptides, 
which are secreted into the environment for defense and niche security. As such, large-scale 
microbial cultures are grown at optimal conditions and cation exchange resin is use to capture 
secreted peptides from the cell-free media following the detailed protocols:  
Fungi: 
Day 1: 
1. Prepare four 5 mL starter cultures of the microbe of interest and grow at optimal 






2. Prepare 1 L each of 25 mM sodium acetate, pH 5.5 (equilibration/wash) and 25 mM sodium 
acetate, pH 5.5, with 1 M NaCl (elution) solutions. 
3. Equilibrate CM Sephadex C-25 resin (GE Healthcare) by weighing out 10 g and hydrating 
in 140 mL of equilibration buffer. Stir slowly at 4℃ for two days. 
Day 5: 
4. Add all 4 starter cultures to 2 L of media and grow to late-log phase at optimal growth 
conditions. 
5. Remove cells by centrifugation (500 x g for 5 minutes) and carefully decant supernatant 
into a new flask without disturbing the cell pellet. 
6. Adjust supernatant to a pH of 5.5 and stir overnight with the hydrated resin. 
Day 6: 
7. Transfer peptide-resin slurry into centrifuge bottles and gently centrifuge (500 x g for 5 
minutes) the beads to the bottom of the bottle. 
8. Decant (save, and label as flow through) remaining liquid from the bottle. Add enough 
wash solution to cover the resin (~50 mL), gently swirl in bottles for ~5 minutes, and 
repeat the centrifugation process. 
9. Continue to wash and collect resin 5x (save, label as wash #). 
10. After 5 washes, add enough elution solution (~50 mL) to cover the resin, swirl, 
centrifuge, and decant (save, label as elution #). Repeat elution step 5 times. 
11. Buffer exchange and concentrate elution fractions 10X into 5 mM ammonium formate, 
pH 2.7 using 3 kDa spin concentration filters (Millipore). Combine concentrated elutions 







1. Prepare 1 L each of 25 mM sodium acetate, pH 5.5 (equilibration/wash) and 25 mM sodium 
acetate, pH 5.5, with 1 M NaCl (elution) solutions. 
2. Equilibrate CM Sephadex C-25 resin (GE Healthcare) by weighing out 10 g and hydrating 
in 140 mL of equilibration buffer. Stir slowly at 4℃ for two days. 
Day 2: 
3. Prepare four 5 mL starter cultures of the microbe of interest and grow until late-log phase 
at optimal temperature (usually 37℃) with shaking. 
Day 3: 
4.  Add all 4 starter cultures to 2 L of media and grow to late-log phase at optimal growth 
conditions. 
5. Remove cells by centrifugation (500 x g for 5 minutes) and carefully decant supernatant 
into a new flask without disturbing the cell pellet. 
6. Adjust supernatant to a pH of 5.5 and stir overnight with the hydrated resin. 
Day 4: 
7. Transfer peptide-resin slurry into centrifuge bottles and gently centrifuge (500 x g for 5 
minutes) the beads to the bottom of the bottle. 
8. Decant (save, and label as flow through) remaining liquid from the bottle. Add enough 
wash solution to cover the resin (~50 mL), gently swirl in bottles for ~5 minutes, and 





9. Continue to wash and collect resin 5x (save, label as wash #). 
10. After 5 washes, add enough elution solution (~50 mL) to cover the resin, swirl, 
centrifuge, and decant (save, label as elution #). Repeat elution step 5 times. 
11. Buffer exchange and concentrate elution fractions 10X into 5 mM ammonium formate, 
pH 2.7 using 3 kDa spin concentration filters (Millipore). Combine concentrated elutions 
for creation of crude extract. 
2.4 Peptide Library Generation 
After selective extraction (plants) or harvesting (microbes) of small cationic peptides, 
extracts are crudely fractionated using strong cation exchange chromatography on a 
PolySulfoethylA column (100 x 4.6 mm, 3 μm particles). Briefly, 400 μL of each extract is 
injected on column and eluted using a high salt gradient (mobile phase A: 5 mM ammonium 
formate, 20% ACN, pH 2.7; mobile phase B: 500 mM ammonium formate, 20% ACN, pH 3.0). 
Salt gradients have been optimized for plant extracts (Figure 2.1a) and microbial extracts (Figure 
2.1b). Fractions are collected in one-minute intervals across the entire run and desalted 3x with 
MilliQ water using a vacuum concentrator to remove salts toxic to microbial cells. Desalted 
fractions are stored for short periods at 4°C if downstream analysis will happen immediately 
after desalting, or at -20℃ until further use. Freeze-thaw cycles should be minimized and 
bioactivity screening and LC-MS analysis should happen as close together as possible. A 
detailed protocol for Shimadzu HPLC operation, sample injection, and fraction collection in the 
context of peptide library creation has been developed and is described below: 
1. Preparation of Mobile Phases: 





b. Sonicate mobile phases in a bath sonicator with loosened caps for 1 hour to de-gas 
solutions.  
c. Save ~10 mL of MPA in a falcon tube to use as a blank. 
d. With the pumps turned off, switch out the mobile phases by removing the cap and 
attached tubing off of the first bottle, rinsing with dH2O, wiping with a kimwipe, and 
inserting into new mobile phase. Repeat with mobile phase B. (Note: The lines are 
labeled with A and B to denote which mobile phase is which). 
2. Sample Preparation: 
a. Thaw extract and centrifuge for 5 minutes at 5000 rpm to pellet out any precipitation. 
b. Add sample to 1 mL vial with at 10% more than the injection volume.  Make sure 
there are no air bubbles in the vial. 
3. Changing the column: 
a. Unscrew the fittings on the old column, undoing the top ferrule first.   
b. Screw in the bottom ferrule of the new column, then the top ferrule.  Fittings should 
be finger tight.  The flow goes from the bottom of the chamber to the top, so make 
sure the flow arrow is pointing upwards. 
c. Turn on the pump and watch the column to make sure there are no leaks. 
4. Creating a Method: 
a. Ensure all components of the LC are turned on and display a green light. 
b. Click on “Instruments.” 
c. Double click on “System 1” – should hear a single beep to know instrument was 
connected properly and you should see “LC Ready” in the upper left corner. 





e. Expand the Instrument parameters view section and navigate the following tabs: 
i. Data Acquisition:  
(a) Change “LC stop time” and “End time” to your run duration. 
ii. LC Time Program: 
(a) Write gradient program. 
(b) Press “Draw curve” to ensure your gradient is written correctly. 
iii. Pump: 
(a) Set “Flow” to your desired flow rate. 
(b) Change the maximum pressure limit to 4500 psi and the minimum pressure 
limit to 0 psi. 
iv. Detector A: 
(a) Use the default settings, changing only the desired detection wavelengths. 
v. Column Oven: 
(a) Set temperature if desired. 
vi. Controller: 
(a) Under external output, check power on. 
(b) Turn autosampler pretreatment off. 
vii. Autosampler: 
(a) Use default settings. 
viii. Autopurge: 
(a) 1st: Mobile Phase A for 10 minutes. 
(b) 2nd: Mobile Phase B for 10 minutes. 





(d) Under Warmup: 
(i) Wait time: 0 minutes. 
(ii) Total flow: 0.5 mL/minutes. 
(e) Check activate system after autopurge. 
f. Save your method file. 
5. Starting the Instrument: 
a. “Wake up” all hardware manually by pressing the sleep button.  Turn on the detector 
by pressing the power button (Orange=Asleep, Green=Awake, Red=Problem). 
b. User Name: LC User, Password: LC User. 
c. Double click “LabSolutions” icon. 
d. Click on “Instruments.” 
e. Double click on “System 1” – should here a single beep to know instrument was 
connected properly and you should see “LC Ready” in the upper left corner. 
f. Open your method file and start the pump: File→Open. 
g. Autopurge following the method settings. Note: You should never autopurge with the 
column oven on.  If the column oven is turned on for your method, press the button 
for “Oven On/Off” before purging. 
h. Run at least 1 blank (MPA) using your method to ensure the instrument is performing 
properly.  
i. Start samples using either the single run, or by creating a batch upload.  
i. Running a Sample: Single Run. 
(a) Open the method file you wish to use. 





(c) Name your Sample. 
(d) Change the file where your data will be stored by clicking on the folder icon 
to the right of “Data file”.  Choose your folder and name the file the same as 
you named your sample. 
(e) Adjust the vial position and injection volume accordingly (max 500 uL or 10 
uL depending on installed sample loop). The tray should always be 1. 
(f) Press “OK” to start the run. 
ii. Running a Sample: Batch Upload. 
(a) Open method. 
(b) Click main in the left tab. 
(c) Press “Realtime batch.” 
(d) Queue up samples. 
(e) Press start realtime batch. 
6. Fraction collection: 
a. The fraction collector runs independently of the Shimadzu. If fraction collection is 
desired, it must be manually started at the beginning of each run. 
b. Before starting the run, align the fraction collector by lining up the dashed line on the 
turn barrel with the dashed line on the stand. Ensure correct alignment by placing an 
empty tube in position 1 and make sure that the fraction collector is dripping into the 
center of the tube. The fraction collector or cannot be adjusted once it is started so 
ensure that alignment is accurate. 





d. Set how frequently the fraction collector should turn by adjusting the buttons on the 
front of the stand (turn after X number of drops or after X time passes). 
e. Start the run on the Shimadzu and watch the computer. Once the sample is injected, 
the run time will officially begin and the fraction collector should be started such that 
the run time is representative of the fraction number. 
7. Shutting down the instrument: 
a. Turn the pump off by pressing the “Pump On/Off” button in LabSolutions. Watch to 
make sure both the flow rate and pressure drop to zero on the instrument display.  
Note: The pump continues to pump 100% MPA after the run(s) have ended.  It will 
run overnight and use all your mobile phase/suck up air if you forget to turn it off. 
b. Turn the column oven off by pressing “Oven On/Off” if applicable. 
c. Close both your method and LabSolutions.  You should hear a beep to let you know 
the instrument is disconnected. 
d. Sleep the computer. 
e. Manually press the sleep button on both pumps, the autosampler, and the column 
oven (status lights should turn orange).  Turn the detector completely off by pressing 
the power button until it pops out – this is to save lamp hours (status light should be 
off).  The status light on the control bus should remain green.   
8. Viewing Previous Runs: 
a. Open LabSolutions. 
b. Click Postrun on left. 
c. Double click Postrun icon. 





e. Highlight, drag, and drop your desired file in top graph.  Note: multiple files can be 
highlighted at once and dragged/dropped together to compare two or more runs. 
f. Click and drag around trace on top graph to zoom in on features.  The zoomed in 
section will show up on the bottom graph. 
9. Troubleshooting:  
a. Refer to the troubleshooting guide on the Hicks Lab Sharedrive 
(Lab_Documents/Protocols/Shimadzu HPLC Troubleshooting Guide) for common 
issues. 
2.5 Bioactivity Screening 
Bioactive peptides have been shown to exhibit a wide range of bioactivities, including 
antibacterial, antifungal, and anticancer activity. As such, assays have been developed to probe 
the intrinsic bioactivities of natural product peptide libraries generated with PepSAVI-MS. All 
assays rely on the addition of the peptide library to an early log phase microbial culture or cell 
line, and subsequent quantification of remaining viable cells after an optimized incubation 
period. For all assays, it is crucial to use correct sterile technique for accurate and reproducible 
results.  
2.5.1 Antibacterial Activity 
For initial antibacterial screening, an assay against the gram-negative bacterium Escherichia 
coli (ATCC 25922) has been developed. Peptide libraries are pre-screened for strong activity 
against E. coli to prioritize fraction sets for further screening against the clinically relevant 
ESKAPE pathogens. Bioactivity assays for a subset of the ESKAPE pathogens are currently 
being established and optimized in our laboratory. A collaboration with the laboratory of Dr. Les 





of ESKAPE pathogens. For any bacterial pathogen, cell culture is mixed with each plant fraction 
in microtiter plates and is incubated for 2-4 hours to allow sufficient time for bacterial growth. 
Cell viability is assessed using Resazurin, an oxidation-reduction indicator dye that quantifies 




)) ∗ 100%. The detailed protocol for antibacterial assay 
setup and analysis is as follows: 
Day 1: 
1. Streak a Mueller Hinton agar plate with bacteria from the appropriate freezer stock.  Use 
quadrant streaking to produce isolated colonies (16 hours at 37°C for E. coli).  Store at 
4°C between uses. Plates are stable at 4℃ for one week.  
Day 2: 
2. Using an inoculating stick, transfer a single colony from the plate to 5 ml of Mueller 
Hinton Broth (MHB, Difco) in a 14 mL culture tube. Incubate at 37°C with shaking (250-
325 rpm) overnight (16 hour incubation e.g. 5pm – 9 am or 6 pm – 10 am). 
Day 3: 
3. Check optical density at 600 nm and subculture appropriately to produce (after further 
growth for 1 hour at 37°C) a culture with an OD600 of 0.5. If the OD is above 1.0, dilute 
your culture to obtain an accurate read. 
a. For S. aureus and A. baumannii, calculate volume of culture needed for final 
density 0.35 in 5 ml MHB.  
b. For E. coli and K. pneumoniae, calculate volume of culture needed for final 





c. Use equation: M1V1 = M2V2  
i. i.e. volume to add = [(5000)(0.25 or 0.35)]/OD600 
4. After 1 hour additional growth, confirm culture density is ~0.5. 
5. Refer to the bioassay plate layout template on the Hicks Lab Sharedrive 
(Lab_Documents/Antimicrobial Peptides/Bioassay Formatting Guidelines_revised_2) to 
determine the location of each component of the assay. Refrain from using the outermost 
wells of the plate to prevent edge effects. Add 50 μL of water to these wells to help 
prevent drying. 
6. For one assay, performed in triplicate, make an 8 ml “master mix” by combining 2 mL of 
2x MHB (Difco), 4 mL of 1x MHB (Difco), and 2 mL of culture. 2x MHB added to 
master mix will always be constant but 1x MHB and culture volumes can be adjusted to 
give correct final OD of 0.125 (This will be 0.10 when fractions are added). 
7. Using a sterile 96 well microtiter dish, a sterile pipetting reservoir, and a multichannel 
pipette, add 40  μL master mix to appropriate wells. 
8. For every replicate, include 4 wells of positive control using 10  μL of antibiotic. 
a. E. coli – use 10  μL of a 1:100 dilution of Amp100 stock (ampicillin, dilute in 
water). 
b. S. aureus, A. baumannii, K. pneumoniae, and E. faecium – use 10  μL of a 1:100 
dilution of Erm100 stock (erythromycin, dilute in water). 
c.   Include 4 wells of positive control culture on each plate.    
9. For every replicate, include 4 wells of a negative control using 10  μL of water in place of 





10. For every experiment include 4 blank wells with 50  μL of 1x media in place of the 
bacterial culture. 
11. Handle the plate carefully and keep level to avoid splashing cultures among adjacent 
wells.  Keep the lid on the plate at all times except when checking OD. 
12. Spin plate briefly in centrifuge to remove bubbles and ensure bottom of each well is fully 
coated with culture/test solutions. 
a. Press and hold the “Short” button until the condensation is knocked off the lid 
(~1500 rpm). 
13. Read OD600 of the plate and verify that the starting OD is about 0.1. 
14. Transfer plate to 37℃ incubator and insert into plate holder. Grow to mid log-phase 
(OD600 of 0.5) with vigorous shaking (250 rpm) for ~4 hours. Resazurin produces reliable 
estimates of metabolic activity at any point in the log-phase, but mid log-phase is a 
convenient point.   
15. Read OD600 of the plate to verify the growth phase of the culture. Use a multichannel 
pipette and a sterile pipetting reservoir to add 1 μL of 50 mM Resazurin (dissolved in 
water and filter sterilized at 0.22 micron) to every well. Centrifuge as in step 11a to 
ensure all resazurin and culture is in the bottom of each well. 
16. Incubate at 37°C for 1 hour with shaking. 
17. Place the adapter/spacer in the plate reader and set parameters for a top read.  Read 
fluorescence with excitation at 544 nm and emission at 590 nm. 






2.5.2 Antifungal Activity 
While AMPs are reported to have broad range activity, the most commonly identified activity 
of plant bioactive peptides is against fungal pathogens1. Two protocols for antifungal activity 
have been developed, the first a high-throughput screening assay using liquid culture as 
described for the antibacterial assays, and the second an agar diffusion-based assay for fungal 
species that fail to grow to high densities in liquid culture, form fungal mats, or do not sporulate 
under these growth conditions. For liquid culture-based assays, the agriculturally relevant 
filamentous fungus F. graminearum was selected. Conidia spores from F. graminearum are used 
for this assay and as such, the following protocol was adapted from The Fusarium Lab Manual3 
for spore germination and collection: 
1. Grow a fresh agar plate of F. graminearium from a frozen spore stock or punch of a 
preserved plate. 
2. Grow fungus until a dense mat is present (~5 days, pink color should be present). 
3. Punch fresh fungal disks from the mat using the back of a 1 mL pipette tip. You will need 
3 disks/50 mL of media. 
4. Make and autoclave 6 x 50 mL flasks of CMC media. Cool media in water bath. 
5. While media is cooling, isolate 3 punches in an empty Petri dish. 
6. Add 3 mL of water to the fungal plugs and cut up the plugs into small chunks with a 
razor blade. 
7. Add the water/spore mixture to one of the 6 flasks. 
8. Repeat steps 5-7 until all 6 flasks contain spores. 
9. Grow flasks at 30℃ with shaking at 120 rpm for three days. 





11. Place a funnel with a layer of miracloth on top of a clean, autoclaved 1L flask. 
12. Pour each 50 mL flask into the bigger flask through the miracloth-covered funnel. 
13. Discard miracloth into autoclave trash and split filtered spores into 50 mL falcon tubes. 
14. Centrifuge falcon tubes at 4000 x g for 20 minutes at room temperature. 
15. Pour off media, resuspend spores in enough water to cover the pellet and spin at 4000 x g 
for 20 minutes at room temperature. 
16. Pour off the water. 
17. Add 25 mL of 20% glycerol to one tube. 
18. Use this liquid to clean out and combine the spores into one tube. Add more glycerol if 
necessary. 
19. Count the cells using the hemocytometer. 
20. Dilute cells to 2.0 x 106 conidia/mL with 20% glycerol. 
21. Prepare 2 mL aliquots from the dilute stock solution. 
22. Flash freeze stocks and store at -80℃ until further use. 
Thawed spore stocks are mixed and incubated with each plant fraction in microtiter plates 
following the adapted bacterial protocol (note: refer to The Fusarium Lab Manual3 for media 
recipes): 
1. For one assay, performed in triplicate, make an 8 ml “master mix” by combining 2 ml of 
Fusarium spores with 6 ml of minimal media (MM).  
2. Using a sterile 96 well microtiter dish, a sterile pipetting reservoir, and a multichannel 
pipette, add 40 μL master mix to appropriate wells. 
3. For every replicate, include 4 wells of positive control using 10  μL of antibiotic. 





4. For every replicate, include 4 wells of a negative control using 10  μL of water.  
5. For every replicate include 4 blank wells with 50  μL of MM in place of the bacterial 
culture. 
6. Handle the plate carefully and keep level to avoid splashing cultures among adjacent 
wells.  Keep the lid on the plate at all times except when checking OD. 
7. Spin plate briefly in centrifuge to remove bubbles and ensure bottom of each well is fully 
coated with culture/test solutions. 
a. Use “Short” button on the centrifuge to spin plates until the condensation is 
knocked off the lid (~1500 rpm). 
8. Read OD600 of the plate and verify that the starting OD is about 0.1. 
9. Transfer plate to 25℃ incubator and insert into plate holder. Grow to mid log-phase 
(OD600 of 0.5) with vigorous shaking (300 rpm) for 2 days.  
10. After 48 hours, read OD600 of the plate to verify the growth phase of the culture.  
11. Add 10 μL of BactiterGlo to each well and return to incubator to shake for 5 minutes. 
12. Read luminescence of each plate on the spectrophotometer using a 500 millisecond 
integration time. 
The number of remaining viable fungal cells are determined in a luminescence assay using 
BacTiter-Glo (Promega) through the quantification of ATP released from the cell lysis. Free 
ATP reacts with luciferase present in the reaction mixture and generates light that is measurable 
via luminescence. Percent activity of each well is calculated as previously described for the 
antibacterial assays.  
Antifungal bioactivity has also been established an agar diffusion-based assay. While this 





densities in low-volume culture or are prone to the formation of fungal mats at high 
concentrations. For these agar diffusion assays, the challenge microbial species is infused into 
the agar. Wells are then carved into solidified agar plates and the peptide library is added, one 
fraction per well. Agar is prepared as a soft agar to allow for compound diffusion. After 
incubation, zones of inhibition form around wells containing active compounds. Measurement of 
each radius of inhibition allows for a measurement of activity across all library fractions.  The 
detailed protocol for agar-based diffusion assays is described below: 
1. Grow dense fungal starter cultures according to optimal growth conditions (typically 5 
days, 25℃, 250 rpm). 
2. On the 6th day, prepare UM media (or other appropriate media) according to 
manufacturer/recipe. 
3. Add 1% agar to liquid media (2.5 g agar for 250 mL media) to make a “soft” agar. 
4. Boil media to dissolve agar and autoclave. 
5. Cool media to 48℃ in a water bath. 
6. Add fungal cultures to cooled media in the ratio of 5 mL fungus/250 mL agar. 
7. Pour fungus-infused agar into Petri dishes and let solidify at room temperature for 1 hour. 
8. Once solidified, carve 4 wells/plate into the agar using the back of a 10 μL pipette tip. 
a. Use a sterile wooden stick to pick up each tip, carefully avoiding touching the top of 
the tip with your gloved hands. 
b. Punch all 4 wells with the same tip and then discard. Change pipette tip after each 
plate to avoid contamination. 
c. Once wells are carved, use a sterile wooden stick to scoop agar out of each well. 





9. Let plates sit for 30 minutes at room temperature before compound addition to dry the 
holes. 
10. Add 50 μL of each compound to a single well in each plate. Fractions should be assessed 
for activity minimally in duplicate. 
11. Use appropriate controls for each challenge species. 
12. Move plates carefully into the static incubator at the appropriate temperature. Keep right-
side-up until you are sure that all of the liquid has diffused into the agar (usually takes a 
couple of hours). Then, flip plates over so that condensation will form on the lid of the 
plate and not the agar. 
13. Let plates grow for 3-5 days until measurable zones of inhibition are observed in the 
positive control. 
14. Measure and record each radius of inhibition by measuring the diameter of inhibition and 
dividing by two. 
While most often used to assess antifungal activity, these agar diffusion-based assays can 
also be used for recalcitrant bacterial species. This was the case with Enterococcus faecalis and 
as such, agar diffusion assays with minor modifications were used to assess the activity of this 
library as described in Chapter 5.  
2.5.3 Anticancer Activity 
Anticancer assays have been established in collaboration with Dr. David Hoskin at Dalhousie 
University in Nova Scotia and with Dr. Mike Emanuele at the University of North Carolina at 
Chapel Hill. Assays have been developed for preliminary screening against three cell lines: 
MDA-MB-231 breast cancer, OVCAR-3 ovarian cancer, and PC-3 prostate cancer. Screening 





studies. All of the anticancer screens performed in this dissertation are in collaboration with the 
Hoskin Lab. However, a newly established collaboration with the Emanuele Lab allows for 
easier and faster anticancer analysis, and will serve as a route for preliminary screening to 
identify highly active peptide libraries that will undergo the full anticancer panel. 
Hoskin Lab Protocol: 
Day 1: 
1. Grow cells in the appropriate growth medium and plate into a 96-well flat-bottom 
microtiter plates at 2 × 104 cells/well.  
2. Culture cells for 24 hours in a 37℃ humidified incubator to allow for formation of 
adherent monolayers.  
Day 2: 
3. Remove medium and replace with fresh serum-free medium with or without individual 
plant fractions to be assayed for cytotoxic activity.  
4. Culture cells for an additional 24 hours. 
Day 3: 
5.  Two hours before the end of culture, add 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution to each well at a final concentration of 0.5 
mg/mL to measure mitochondrial succinate dehydrogenase activity.  
6. Discard culture supernatants. 





8. Measure absorbance at 570 nm and compare to the control to determine percent reduction 
in viability, as reflected by the change in mitochondrial succinate dehydrogenase activity. 
Emanuele lab protocol: 
Day 1: 
1. Seed 10,000 MDA-MB-231 breast cancer cells/100 μL media/well into a 96-well plate 
(93 wells with cells, 3 wells without cells). 
2. Allow for overnight adherence.  
Day 2: 
3. In the morning, carefully remove media from each well without disturbing cells.  
4. Replace with 90 μL of fresh media in each well. 
5. Add 10 μL of each fraction to the cells. Initial activity assessment is performed in singlet. 
Any active peptide libraries will be re-screened in triplicate. 
6. Incubate at 37℃ for 24 hours. 
Day 3: 
7. In the morning, carefully remove the media from each well without disturbing the cells. 
8. Replace with 90 μL of fresh media in each well. 
9. Prepare 5 mg/mL of MTT solution in PBS. 
10. Add 10 μL of 5 mg/mL MTT solution to each well and incubate for 2 hours at 37℃. 
11. Carefully remove media from each well without disturbing cells.  
12. Add 100 μL of DMSO to each well and mix by pipetting up and down. Be sure to add 





13. Incubate at 37℃ for 15 minutes. 
14. Measure absorbance at 570 nm and calculate percent activity. 
2.5.4 Shipping Peptide Libraries  
Collaborations with the Shaw Lab at USF and the Hoskin Lab at Dalhousie University have 
been established for ESKAPE pathogen screening and cancer screening, respectively. As such, 
peptide libraries must be shipped to each location. For best results, it is crucial that all analysis is 
done with the same peptide library on the same time frame to minimize the possibility of peptide 
degradation. As such, two peptide libraries from the same species should be fractionated on the 
same day and then combined to obtain 500 μL of each fraction. This volume is sufficient for 
either a full panel of ESKAPE pathogens or anticancer assays and half of the ESKAPE 
pathogens. If the full analysis is desired, 3 or 4 peptide libraries should be combined before 
analysis. Combined library should then be aliquoted into separate microtiter plates with the 
appropriate volume for analysis at each location (e.g. one plate for E. coli bioactivity and LC-MS 
analysis with 80 μL/well and one plate for ESKAPE pathogen screening with 420 μL/well). 
Plates being sent to collaborators should be tightly sealed using a well plate matt and stored at -
20℃ until shipment. Plates should be shipped on a weekday (Monday – Thursday) via FedEx on 
dry ice with overnight delivery. 
2.6 LC-MS/MS Analysis 
LC-MS/MS analysis is used to obtain peptide abundance data across fractions 11 – 40  in 
each peptide library. Early and late-eluting fractions are excluded to avoid instrument 
contamination via highly abundant small molecules and high salt concentrations, respectively. 
For most peptide libraries, a dilution ratio of 5 μL of peptide fraction into 45 μL of 95% 





MS. However, it is recommended to pick a representative fraction based off 280 nm SCX 
chromatogram (usually between 18 and 25), start with a lower (5:100) dilution ratio, and increase 
concentration 2-fold until the optimal loading level is achieved. Once the desired dilution ratio is 
determined, prepare all of the remaining fractions at the same concentration (crucial for relative 
quantification across fractions) in a low-volume 96-well plate and cover with an adhesive plate 
seals.  
Fractions are analyzed using a Waters nanoAcquity UPLC coupled to a Sciex TripleTOF 
5600 mass spectrometer, following the parameters outlined in Tables 2-1 and 2-2. Five μL of 
each sample is injected onto a Waters Symmetry C18 trap column (5 μm particles, 180 μm ID, 
20 mm length) before subsequent passing onto a Waters HSS T3 C18 column (1.8 μm particles, 
75 μm ID, 250 mm length) analytical column. The LC employs a two-step linear gradient of 
increasing mobile phase B (step 1: 5-50%, step 2: 50-85%) over 60 minutes for peptide 
separation (Table 2-1). Electrospray ionization is used to generate gaseous ions. LC-MS/MS data 
is collected in positive ion, high sensitivity mode, using information dependent acquisition (IDA) 
of the first 20 ions for MS/MS. A BSA calibration run should be included after every 8 samples 
to ensure high mass accuracy. 
All LC-MS data is processed using Progenesis QI for Proteomics software (Waters). 
Progenesis QI is a label-free proteomics software that enables peak alignment and quantification 
over multiple LC-MS runs. To align runs, allow the software to choose a reference run from a 
select subset of fractions (usually between 15 and 35) that elute over the SCX gradient and 
contain the region of activity. Apply automatic processing settings with a retention time filter 
using a minimum peak with of 0.1 minutes to align and peak pick ions across all runs. Peaks that 





across all fractions, we are able to track changes in abundance of each individual ion detected 
across SCX fractions and thus relate these changes to the changes in bioactivity. All data should 
be exported at the ‘peptide ion’ stage. 
2.7 PepSAVI-MS Statistics 
Exported peptide ion data is subject to PepSAVI-MS statistical analysis for determination of 
most-likely components contributing to the observed bioactivity. PepSAVI-MS statistics are 
implemented in R and have been developed into a publicly available CRAN package, 
PepSAVIms (https://cran.r-project.org/package=PepSAVIms). Development of the PepSAVIms 
statistical analysis package was performed in collaboration with the Liu Lab at UNC Chapel Hill. 
Graduate student David Pritchard wrote the code behind each function and helped to author the 
package vignettes, which serve as the basis of this section. 
The PepSAVIms statistical analysis pipeline consists of three core functions: binMS, 
filterMS, and rankEN. The prototypical workflow for analysis in our laboratory is highlighted by 
the solid lines in Figure 2.2, using all three functions, in order, to extract a ranked compound list. 
However, the binMS and filterMS functions are optional workflow steps that may not be 
necessary for data generated from different mass spectrometers utilizing different peak picking 
software. Instead, this data can be imported and organized using the msDat feature before 
rankEN analysis. In all cases, bioactivity data is required at the rankEN step.  
2.7.1 Binning of Mass Spectrometry Data: Using the binMS Function 
Binning of mass spectrometry data is used to refine the data matrix generated from peak 
picking software. As PepSAVI-MS relies on the quantification of all species regardless of 





achieve this is to increase the sensitivity of the peak picking software; however, it has been 
observed that this often results in the same compound being ‘picked’ multiple times due to shifts 
in retention time or mass accuracy across fractions. As such, the binMS feature was designed to 
identify and group compounds designated as different using the peak picking software, but seem 
to be the same after accounting for mass accuracy and retention time figures of merit associated 
with the available LC-MS/MS system.  
BinMS uses m/z, charge, and retention time parameters to determine compounds that should 
be binned together, according to the following notation:  
binMS (mass_spec, mtoz, charge, mass, time_peak_reten, ms_inten, time_range, 
mass_range, charge_range, mtoz_diff, time_diff) 
The mass spectrometry data matrix must be loaded as a .csv file into R, and is called into the 
binMS feature as ‘mass_spec’. ‘Mtoz’, ‘charge’, ‘mass’, ‘time_peak_reten’, and ‘ms_inten’ 
values are parameters present in the mass spectrometry data matrix and are can be identified by 
the binMS function by column number or a unique column identifier. Retention time, mass, and 
charge filters can be employed using the ‘time_range’, ‘mass_range’, and ‘charge_range’ 
parameters to exclude compounds eluting during wash/equilibration or compounds too large or 
small to be considered bioactive peptides. The last 2 parameters of the binMS feature specify the 
requirements for two rows to be binned together. ‘Mtoz_diff’ specifies the largest allowed 
difference in two m/z ratios for the features to be considered for binning. Similarly, the 
‘time_diff’ parameter specifies the largest allowed shift in retention time for two compounds to 





Once all parameters are specified, the binMS feature begins by identifying the m/z ratio of 
the first compound and comparing it to every other feature in the spreadsheet. If both the 
‘mtoz_diff’ and ‘time_diff’ criteria are satisfied, and the charge state of the two features is 
identical, the two rows will be binned together, averaging all parameters associated with 
compound identification and summing intensity values. This newly binned row is then compared 
to all other rows in the spreadsheet until no further binning can occur. Then, the next feature is 
selected for binning until all features have been considered. The resulting binned rows can be 
written into a new data matrix and exported as a .csv file. For our LC-MS platform, binning with 
the thresholds of 0.05 m/z and 5 minutes retention shift generally produces accurate binning. 
However, data should be manually interrogated to investigate the optimal binning thresholds for 
each data set.  
2.7.2 Filtering of Mass Spectrometry Data: Using the filterMS Function 
Binned mass spectrometry data is then filtered for compounds likely contributing to the 
observed bioactivity profile(s) using the ‘filterMS’ function, as follows: 
filterMS (msObj, region, border, bord_ratio, min_inten, max_chg) 
If binning was used, the output .csv should be the input mass spectrometry object, ‘msObj’. 
However, mass spectrometry can enter directly into the filterMS function if desired using the 
MsDat function for formatting. ‘Region’ specifies the filtering region, as designated by the 
observed bioactivity profile. As mass spectrometry analysis is more sensitive than bioactivity 
measurements, filtering should allow for the active compound to be present in + two fractions on 
either side of the bioactivity profile, designated as the extended bioactivity region. Typically, all 





if desired. The ‘bord_ratio’ specifies the maximum allowed abundance of a compound outside of 
the bioactivity region, and is relative to the maximum observed abundance of that feature, only. 
To eliminate noise, peak picked data can also be filtered through requirement of a minimum 
intensity value or maximum charge value, as designated by ‘min_inten’ and ‘max_charge’. 
FilterMS uses the input mass spectrometry data to filter out any compounds unlikely to be 
causing the observed bioactivity using the idea that if a compound is causing the activity, it 
should be maximally abundant in the fractions where bioactivity is observed (controlled by the 
‘region’ and ‘border’ parameters). Following the same logic, that compound should not be highly 
abundant in any outside fractions where bioactivity is not observed (controlled by the 
‘bord_ratio’ parameter). For the typical PepSAVI-MS dataset, the extended bioactivity region is 
most commonly between 5 and 7 fractions, and border ration of 0.05 (5%) is used. All 
compounds meeting the filterMS criteria are written into a new .csv file for entry into the 
rankEN function. 
2.7.3 Penalized Linear Regression for Putative Bioactive Peptide Determination: Using 
the rankEN Function 
Filtered compounds are subject to penalized linear regression to determine features with 
profiles most-closely matching the observed bioactivity profile using the rankEN function: 
rankEN (msObj, bioact, region_ms, region_bio, lambda, pos_only, ncomp) 
The output from the filterMS function serves as the ‘msObj’ input for the rankEN function. 
Bioactivity data across all fractions with corresponding mass spectrometry data is required to 
implement this function of the PepSAVIms package, and is called to the rankEN function as 
‘bioact’. The ‘region_ms’ and ‘region_bio’ parameters specifications designate the mass 





unique column identifier. Lambda specifies the penalty parameter to be used in the elastic net 
estimation, typically 0.01 for PepSAVI-MS data sets. The ‘pos_only’ feature allows only 
compounds with a positive correlation to be considered for modeling, and ‘ncomp’ specifies the 
maximum number of compounds the function should report.  
The rankEN function employs penalized linear regression with an elastic net estimator to 
determine compounds most-likely contributing to the observed bioactivity. Penalized linear 
regression is a regression method that imparts a penalty each time a compound enters the model, 
with the ultimate goal of obtaining a subset of compounds that minimizes the loss function. The 
rankEN function works by selecting a choice of quadratic penalty parameter, and for fixed value 
of quadratic penalty parameter tracking the order in which the coefficients corresponding to 
candidate compounds first become nonzero along the elastic net path as the 𝓁1 penalty parameter 
changes4. It is presumed that compounds with corresponding coefficients that become nonzero 
earlier in the path may be better candidates for having an effect on bioactivity levels then those 
with corresponding coefficients that become nonzero later in the path. A small, nonzero value is 
recommended for the quadratic penalty parameter in this instance. This value will approach the 
lasso penalty while bypassing the lasso limitation of selecting no more than one less than the 
number of bioactivity data points of nonzero coefficients, thus severely reducing the size of the 
list of candidate compounds5. In the end, the rankEN function returns identifying information for 
each compound in the order in which the corresponding regression coefficient for a given 
compound first becomes nonzero as part of the Elastic Net path. 
2.7.4 General Usage 
An example of the fully coded PepSAVIms statistical analysis is depicted in Figure 2.3. The 





be loaded for use of core functions. Blue colored files serve as input files for each function, and 
orange files as the corresponding output. Optional functions are depicted in green. These 
functions are useful to ensure that data is being read in to R properly, and to display column 
headers useful for designating column numbers within each function. However, these functions 
are not required for package use. Each core function is equipped with a corresponding summary 
function that displays the number of compounds entering and exiting the compound after each 
round of analysis. It is highly advised to write the compounds remaining after each stage to a 
unique .csv file to ensure proper function and for use in troubleshooting. 
2.8 Peptide Prioritization and Target Identification  
Top 20 ranked compounds are considered the initial candidates for identification and 
purification, with priority starting with the highest ranking compounds or compounds appearing 
in ranked lists for multiple target species. As no peptide deconvolution is used, each peptide 
charge state or adduct is considered a unique feature and is allowed to enter the model 
individually. While this compound redundancy limits the number of unique compounds that 
enter the model, identification of a single peptide with multiple charge states/adducts ranking in 
the top 20 compounds serves as an additional level of confidence and can be used for further 
peptide prioritization.  
Initial MS/MS analysis includes collision induced dissociation of the first 20 compounds 
meeting the fragmentation criteria. While this generates some level of sequence information for 
compounds on the top 20 list, targeted fragmentation is typically required after peptide 
prioritization. This can be achieved using parallel reaction monitoring (PRM) or an information 
dependent acquisition (IDA) experiment with an inclusion list using the fraction with the highest 





sequenced genomes, de novo sequencing is used for natural product peptide identification. De 
novo sequencing of each compound is performed using the de novo graphical user interface 
(GUI) in conjunction with manual sequencing6. If only partial sequences can be obtained, 
sequence tags can be searched against a related species to serve as a starting point for peptide 
assignment.  
2.9 Peptide Isolation 
Target peptides must be isolated or synthesized for activity validation and exploration of 
activity against a complete bioactivity panel. Peptide synthesis is the preferred route forward for 
linear, unmodified peptides with complete sequences. To enable production of peptides and 
small proteins, Fmoc-based solid-phase peptide synthesis (SPPS) will be performed in 
collaboration with the Womack Lab at High Point University using a flow chemistry-based 
platform built in-house7-8. Using this proven instrument, peptide fragments are rapidly generated 
and further purified with modern chromatography methods. If sequence determination is difficult 
or ambiguous, or if it is not feasible to synthesize the identified peptide, isolation from source 
material will be conducted using the applicable chromatographic chemistry. While this approach 
is more labor intensive and will require chromatographic optimization, it allows for the isolation 
of complex/difficult-to-sequence peptides.  
2.10 Minimum Inhibitory Concentration (MIC) Determination 
Purified peptide(s) will be subject to an array of relevant bioactivity screens determined by 
the initially observed activity. Minimum inhibitory concentrations will be determined using a 
dilution series of isolated peptide against each target pathogen. Minimum inhibitory 







Table 2-1 Liquid chromatography conditions. 
LC conditions: 
LC system Waters nanoAcquity 
Mobile phase A (MPA) Water with 0.1% formic acid 
Mobile phase B (MPB) Acetonitrile with 0.1% formic acid 
Trap column Waters Symmetry C18 trap column (5 μm particles, 180 μm ID, 20 mm length) 
Trapping conditions 5 uL/minute, 100% MPA for 3 minutes 
Analytical column HSS T3 C18 column (1.8 μm particles, 75 μm ID, 250 mm length) 
Flow rate 0.3 μL/min 
Run time  60 minutes 
 
Gradient: 
Time (minutes) % MPA % MPB 
0 95 5 
1 95 5 
31 50 50 
33 15 85 
36 15 85 
37 95 5 







Table 2-2 Mass spectrometry acquisition parameters. 
 
Mass spectrometry acquisition parameters: 
MS system AB Sciex TripleTOF 5600 
Ionization Electrospray 
Operation Positive-ion, high sensitivity mode 
Survey spectrum (MS1) mass range 350 – 1600 Da 
Survey spectrum acquisition time 250 ms 
MS2 mode Information-dependent acquisition (IDA) 
MS2 selection criteria First 20 features >150 counts/second with charge state +2 to +5 
Collision energy Rolling (+ 5%) 
MS2 exclusion window 8 seconds 
Total cycle time 2 seconds 




















Figure 2.2 PepSAVIms statistical analysis workflow, adapted from the PepSAVIms CRAN 
package vignette. Solid lines represent the prototypical workflow for the Hicks Laboratory, and 






setwd("/Users/Christine/Documents/Hicks Lab/Statistical modeling/20180227_EPu_SCX2 modeling") 
library(“devtools”, “lars”, “elasticnet”, “PepSAVIms”) 
MSdata<-read.csv("20180227_CLK_BAP_EPu_4x_SCX2_fractions_peptide ion data_clean.csv") 
names(MSdata) 
MSdata[1:5, 1:5] 




filterMS_out<-filterMS(binMS_out, paste0("SCX2_",25:31), border = "all", bord_ratio = 0.1, min_inten = 1000, 






rawMsDat<-msDat(MSdata1, 2, 3, ms_inten=4:33) 
bioactivity<-read.csv("20171115_EPu 4x bioassay_data only.csv") 
bioactivity 
dim(bioactivity) 
E.coli        <- bioactivity[1L, ] 
save(rawMsDat, 
     E.coli, 
     file="20180227_EPu_SCX2_combined MS and bioactivity.RData") 
load("20180227_EPu_SCX2_combined MS and bioactivity.RData") 
orderedCompds_E.coli<-rankEN(rawMsDat,E.coli, paste0("SCX2_",26:30), paste0("SCX2_",26:30), 




Figure 2.3 Example R code for PepSAVI-MS statistical analysis, considering typical workflow 
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3.1 Introduction  
Difficult-to-treat nosocomial and community acquired fungal and extensively drug resistant 
bacterial infections are increasingly commonplace, new viral diseases are emerging and 
spreading rapidly, and cancer remains a leading cause of death worldwide. In the US, there are 
almost two million hospital-acquired bacterial infections each year, resulting in ~100,000 
deaths1. The emergence of ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) 
pathogens has led to a significant increase in multidrug resistant (MDR) infections in the clinic 
with associated increases in morbidity and mortality2. Additionally, the recent emergence, 
resurgence, and spread of viruses, including Zika, SARS, West Nile, Ebola, and MERS3, for 
which there are limited or no direct-acting antivirals, highlight the susceptibility of the human 
population to future potentially untreatable pandemics. Furthermore, despite continued progress 
in anticancer therapeutics, limitations to current lead compounds of nonspecific toxicity, poor 
drug penetration, and multidrug resistance have emphasized the need for discovery of anticancer 
therapeutics with novel mechanisms of action4. With many bacteria now unresponsive to 





there is an undeniable and desperate need to identify novel pharmacological chemistries and 
accelerate their development through new methods and innovative technologies.  
Natural products have long been sources of virtually all traditional medicinal preparations 
and have been the single most successful source of lead compounds for drug discovery5. 
Specifically, plants have played a significant role in the treatment of human ailments since 
prehistoric times. The teas and tinctures of times past are one source to drug discovery, allowing 
the ethnobotanically-guided isolation and characterization of pharmacologically active 
compounds for the treatment of bacterial and fungal infections, cancers, and other ailments. 
Despite historical relevance and past success, challenges associated with natural product 
discovery have slowed progress in drug discovery efforts. Additionally, natural product 
discovery efforts have largely focused on small molecule constituents. However, recent 
discoveries have revealed ribosomally-synthesized, post-translationally-modified peptide natural 
products (RiPPs) with substantial structural diversity and bioactivity potential, including novel 
mechanisms of action6-7. While traditionally studied for antifungal and antibacterial properties, 
recent studies have piqued interest in these peptides as potential anticancer therapeutics8. 
Peptides offer several advantages over other small and large molecule drug candidates – 
including greater efficacy, selectivity and specificity relative to small organic molecules, better 
tissue penetration, and reduced immunogenicity and manufacturing costs relative to 
proteins/antibodies. Advances in peptide modification, formulation, and delivery methods can 
address known limitations of peptidic drug candidates9, including modification of peptide 
length/content to increase selectivity10, stapling and/or peptidomimetic conversion techniques to 
improve pharmacokinetic properties11, as well as encapsulation methods to protect from 





screening approaches and elude detection via standard -omic workflows due to their large size, 
structural diversity and high level of post-translational modification; therefore, systematic 
approaches for discovery and characterization are in nascent development12. Developing natural 
product screens for antimicrobially active RiPPs has the potential for discovery of new bioactive 
compounds with novel mechanisms of action able to address the growing problem of 
antimicrobial resistance.  
Current methods for RiPP discovery often rely on bioassay guided fractionation13 or genomic 
mapping12, 14-15 (e.g. Pep2Path, RiPPquest) to facilitate downstream analysis. Relying on iterative 
rounds of chromatographic separations, bioassay guided fractionation is extremely time 
consuming and provides no structural information until late in the discovery process. 
Additionally, this approach often leads to replication of previously known compounds as a bias 
towards highly abundant and highly active compounds is evident. While alternative genomic 
mapping approaches can provide structural information from the beginning, prior genomic 
sequencing and knowledge of peptide biosynthetic pathways is required. Furthermore, this 
approach is unable to provide direct bioactivity information on the target peptide thus 
necessitating downstream isolation and activity screening to determine function and biological 
activity. Recent approaches to address some of these limitations have been proposed16 (e.g. 
Compound Activity Mapping); however, these platforms are specific to small molecule 
identification and do not translate efficiently towards advancing untargeted proteomics 
approaches. 
To this end, we have developed the PepSAVI-MS (Statistically-guided bioactive peptides 
prioritized via mass spectrometry) pipeline for the screening and identification of cationic 





peptides, our platform employs only one round of crude fractionation and relies on the power of 
mass spectrometry and statistics to assign bioactivity to individual components. Furthermore, we 
implement physiologically relevant whole cell bioassays to obtain activity information early in 
the discovery process, thus focusing on only active bioactive peptide targets. Our PepSAVI-MS 
pipeline is adaptable to any natural product source of peptides and can test against multiple 
physiological targets of various cell lines or organisms, including bacteria, fungi, viruses, 
protozoans, and cancer cells. Herein, we demonstrate the PepSAVI-MS pipeline using plant 
material and focusing on peptides with antimicrobial and/or anticancer properties. Proof-of-
principle studies for a known AMP from the plant Viola odorata are presented to validate this 
workflow. Additionally, we use this pipeline to explore novel antibacterial and anticancer 
activities of the Viola odorata cyclotide, cycloviolacin O2. 
3.2 Materials and Methods  
3.2.1 Source Materials and Growth Conditions 
Viola odorata seedlings purchased from Strictly Medicinal Seeds (formerly Horizon Herbs; 
Williams, OR) were grown to mature rosette stage (~6 weeks) in standard greenhouse 
conditions. Seedlings were planted in nutrient-rich soil under controlled temperature (63.5 - 
68.5°F) and light cycle (14-hr light) conditions. Aerial tissue was harvested with immediate flash 
freezing under liquid nitrogen, and stored at -80°C until subsequent extraction. 
3.2.2 Creation of Peptide Libraries 
Extraction. Frozen tissue (100 g) was ground under liquid nitrogen using a mortar and pestle 
and aqueous extracted in 300 mL of 10% acetic acid with protease inhibitors (Roche, 1 tablet/50 
mL) and stirring for 4 hours at 4°C. Insoluble material was pelleted by centrifugation at 13,000 





particulates. Protein concentration filters (MWCO 30kDa; Millipore) were used to remove high 
molecular weight species, and subsequent dialysis (0.1 – 1 kDa cutoff; SpectrumLabs) into 5 
mM ammonium formate pH 2.7 was performed to eliminate small molecule contaminants. The 
sample was concentrated via vacuum centrifugation to 4 mL to generate the final crude extract.  
HPLC fractionation. Extracts were subjected to a 47-minute SCX method using a 
PolySulfoethylA column (100 x 4.6 mm, 3 μm particles, PolyLC). A salt gradient (Figure 3.1) 
was employed using a linear ramp from 5 mM ammonium formate, 20% acetonitrile, pH 2.7 to 
500 mM ammonium formate, 20% acetonitrile, pH 3.0. Fractions were collected across the 47-
minute run in one-minute intervals and desalted with three washes of 1.3 mL water using a 
vacuum concentrator. Peptide libraries were stored in water (400 μL/fraction) at 4°C until 
bioactivity assay.  
3.2.3 Bioactivity Screening 
Bacterial. Escherichia coli (25922) was obtained through ATCC and the ESKAPE pathogen 
strains are clinical isolates that belong to a collection acquired by the Shaw Lab [Enterococcus 
faecium (1449), Staphylococcus aureus (635), Klebsiella pneumoniae (1433), Acinetobacter 
baumannii (1403), Pseudomonas aeruginosa (1423), Enterobacter cloacae (1454)]17. Bacterial 
cultures were synchronized to mid-log phase by inoculating 1 mL of overnight culture into 100 
mL of TSB and incubated for 3 hours, shaking at 37°C. All assays were performed in 96-well 
microtiter plates by adding 10 μL 2x MH broth, 20 μL of 1x MH broth, 10 μL peptide fraction, 
and 10 μL 0.5 OD600 bacteria culture. The addition of 2x broth ensured sufficient nutrients were 
available since the peptide fractions, in water, accounted for 1/5 of the final volume. TSB was 
used to test S. aureus due to its decreased growth rate in MHB. Ampicillin (100 μg/mL) or 





of the plant fraction to serve as the positive control, and water as the negative control. The 
prepared plates were incubated at 37°C, 275 rpm shaking for 1.5 - 4 hours depending on the 
growth characteristic of the organism before 5 μL of the cell viability indicator dye, resazurin 
(1.19 mM), was added to each well. After one additional hour of shaking and incubation, a 
fluorescence read of 544 nm (ex) and 590 nm (em) was collected to measure relative 
fluorescence units for each sample. Percent activity of each well was calculated using the 
formula: % 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  (1 − (
𝑅𝐹𝑈 𝑜𝑓 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛−𝑅𝐹𝑈 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑅𝐹𝑈 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑅𝐹𝑈 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
)) ∗ 100%.  
Cancer cell lines: Cell viability assay. MDA-MB-231 breast cancer cells, OVCAR-3 ovarian 
cancer cells, PC3 prostate cancer cells, or human dermal fibroblasts in the appropriate growth 
medium were plated into 96-well flat-bottom microtiter plates at 2 × 104 cells/well and cultured 
for 24 hours in a 37oC humidified incubator in order to form adherent monolayers. Medium was 
then removed and replaced with fresh serum-free medium with or without individual plant 
fractions to be assayed for cytotoxic activity. Cells were then cultured for an additional 24 hr. 
Two hours before the end of culture, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) solution was added to each well at a final concentration of 0.5 mg/mL to 
measure mitochondrial succinate dehydrogenase activity. Culture supernatants were discarded 
and formazan crystals were solubilized in 0.1 mL of dimethyl sulfoxide. Absorbance was 
measured at 570 nm on an ASYS Expert 96 plate-reader (Montreal Biotech Inc., Kirkland, QC). 
Absorbance in each treatment group was compared to the control to determine percent reduction 





3.2.4 LC-MS/MS  
Peptide libraries were analyzed via a nano-LC-ESI-MS/MS platform: nanoAcquity (Waters, 
Milford, MA) coupled to a TripleTOF5600 (AB Sciex, Framingham, MA). Peptide fractions 
were diluted to the appropriate loading level, acidified with formic acid and transferred to low-
volume 96-well plates covered with adhesive plate seals. Each sample was injected onto a trap 
column (NanoAcquity UPLC 2G-W/M Trap 5 μm Symmetry C18, 180 μm x 20 mm: Waters) 
before subsequent passing onto the analytical C18 column (10k PSI, 100 Å, 1.8μm, 75μm x 250 
mm: Waters). Peptide separation was carried out at a flow rate of 0.3 μL/minute using a linear 
ramp of 5 – 50 % B (mobile phase A, 1% formic acid; mobile phase B, 1% formic acid in 
acetonitrile) over 30 minutes. The MS was operated in positive ion, high sensitivity mode with 
the MS survey spectrum using a mass range of 350-1600 Da in 250 ms and information 
dependent acquisition (IDA) of MS/MS data. The first 20 features above 150 counts threshold 
and having a charge state of +2 to +5 were fragmented using rolling collision energy +5%. Auto 
calibration was performed every eight samples (8 hours). The data have been deposited to the 
ProteomeXchange Consortium via the PRIDE18 partner repository with the dataset identifier 
PXD004780. De-isotoped peak lists for each fraction were generated using Progenesis QI for 
Proteomics software (Nonlinear Dynamics, v.2.0). To align runs, a reference run was chosen 
from a subset of bioactive fractions (15 - 30 for V. odorata). Automatic processing settings with 
a retention time filter of 14 - 45 minutes were used to align and peak pick ions across all runs. 
Identified features were quantified using AUC integration of survey scan data based on the 
summed intensity of each de-isotoped feature. Data was exported as “peptide ion data” with the 
default parameters from Progenesis at the “Identify Peptides” stage in the software. Our analysis 





3.2.5 Data Reduction and Statistical Modeling 
Areas of interest in the bioactivity profile were selected for subsequent data reduction and 
modeling. The bioactivity region for each V. odorata data set was defined for each pathogen 
based on the observed bioactivity profile as follows: ovarian cancer (18-22), breast cancer (18-
22), prostate cancer (18-22), A. baumannii (17-21), E. faecium (17-21), P. aeruginosa (18-21), E. 
coli (18-25), F. graminearum (19-24). Using the PepSAVI-MS software, background ions were 
eliminated through retention time, mass, and charge state filters to reduce the data to potential 
compounds of interest. Peak-picked data believed to belong to the same MS feature were binned 
together if their m/z values were within a 0.05 Da window and their charge states were identical. 
Next, workflow-informed filtering criteria were applied using the following rules: 1) m/z 
intensity maximum must fall inside the range of the bioactivity “area of interest”, 2) the m/z 
intensity of species meeting the first criteria must be <1% of its respective maximum peak 
intensity in the areas bordering said “area of interest”, 3) there must be non-zero abundance in 
the fraction following the maximum intensity fraction, 4) the maximum intensity must be > 
1,000 in active window, 5) all charge states > +10 are excluded. All m/z species meeting these 
filtering criteria were modeled using the elastic net estimator with a quadratic penalty parameter 
specification of 0.001 to determine each species’ contribution to the observed overall bioactivity 
profile. The resulting list contains candidate compounds ranked in order of when they entered the 
model, such that the highest ranked compounds have the greatest likelihood to be contributing to 
the bioactivity.  
3.2.6 Isolation of cyO2  
Dried aerial plant material from Viola odorata (Alfred Galke GmbH, Bad Grund, DE) was 





minor modifications19. Briefly, ground plant material was subjected to extraction with 60% 
methanol in water, followed by filtration and liquid–liquid extraction with dichloromethane. The 
polar phase was diluted and acidified before subjected to a strong cation exchange 
chromatography to capture cyclotides of net positive charge. Individual cyclotides, i.e. cyO2, 
were then isolated using RP-HPLC. Final cyO2 was of >95% purity assessed by RP-HPLC (214 
nm). 
3.2.7 Validation of cyO2 Activity  
Minimum inhibitory concentration determination of cyO2 against E. coli and A. baumannii 
was performed in Mueller-Hinton media using a broth microdilution method. Bacteria were 
grown overnight and added to the assay at 105 CFU/mL and turbidity/clearing was observed after 
20 hours of incubation. Assay was performed in triplicate starting with 10 or 25 μM cyO2 for E. 
coli or A. baumannii, respectively, and using 2x serial dilution. Mean MICs of 5 and 15 μM were 
obtained for each species, respectively. The mean IC50 value of 6.6 μg/mL for cyO2 against the 
PC3 prostate cancer cell line was determined using duplicate measurements of the MTT cell 
viability assay as described above. 
 
3.3 Results and Discussion  
3.3.1 Overview 
Relying on a multi-pronged approach, the PepSAVI-MS pipeline utilizes selective extraction 
and fractionation of peptide source material, bioactivity screening, and statistics-guided mass 
spectrometry-based peptidomics for the targeted identification and characterization of only 





focusing bioactive peptides from the plant kingdom and their activity against a panel of 
microbial pathogens and cancer cell lines. 
3.3.2 Plant Selection, Cultivation, and Harvesting  
Plant species are selected based on several criteria including known bioactivity of the plant, 
traditional use, and availability. While many plants are commonly used for their perceived 
health-related benefits, the bioactive peptides from these species have not been comprehensively 
evaluated. Seeds/seedlings of selected species are obtained through commercial sources and 
grown in a laboratory greenhouse. Tissue is harvested with immediate flash freezing in liquid 
nitrogen for future extraction.  
3.3.3 Peptide Library Creation  
Preparation of crude extracts from plant material includes aqueous extraction and size 
exclusion to selectively target AMP-like molecules, i.e. water-soluble compounds that are 
smaller than 10 kDa20-21. Extracts are crudely fractionated using strong cation exchange (SCX) 
chromatography such that individual peptides elute over multiple sequential fractions. The 
distribution of bioactive peptide abundance across sequential fractions is reflected in the 
distribution of activity seen in bioactivity data for the same fractions. As peptides are eluted 
using volatile salts during SCX, peptide libraries are simply desalted via vacuum concentration 
for compatibility with downstream bioassays (Figure 3.2a). Peptide libraries can be created from 
constitutive expression, as well as from abiotic and biotic stresses known to induce production of 
defense compounds22-25.  
3.3.4 Bioactivity Screening 
Peptide libraries are assayed for growth inhibition against pathogens of interest using 





incubated with a microbial or cancer cell culture and the presence of bioactive peptides in a 
given fraction will result in inhibition of culture growth during the incubation period. For 
bacterial assays, the remaining viable cells are quantified indirectly by spectrophotometric 
measurement of the irreversible intracellular reduction of resazurin26. For anticancer bioactivity, 
cytotoxicity assays are performed using MTT-based assays to measure mitochondrial succinate 
dehydrogenase activity with absorbance measurements at 570 nm. Values for each fraction are 
compared to positive and negative controls containing a known therapeutic or water, 
respectively, to determine a percent activity of each library fraction, where a small value of 
remaining viable cells indicates high activity. Species with bioactivity profiles of interest are 
prioritized for LC-MS/MS and downstream statistical analysis. 
3.3.5 MS Profiling, Data Reduction, and Statistical Modeling to Identify Putative 
Bioactive Peptides 
Peptide libraries are analyzed via nanoLC-ESI-MS/MS to obtain accurate intact mass and 
relative intensity information for peptide constituents contained within each library fraction 
(Figure 3.2c). The resulting data array is processed using the developed PepSAVI-MS software 
package. Using this function, unwanted compounds can be eliminated using mass, charge, and 
retention time filters. Remaining compounds are binned to condense all of the hits for a given 
m/z ratio into a single feature. Binned datasets are then filtered using the following workflow-
informed criteria to narrow the library to those peptides most likely contributing to the 
bioactivity profile: 1) m/z intensity maximum must fall inside the range of the bioactivity “area 
of interest”, 2) the m/z intensity of species meeting the first criteria must be <1% of its respective 
maximum peak intensity in the areas bordering said “area of interest”, 3) there must be non-zero 
abundance in fraction following the maximum intensity fraction, 4) the maximum abundance 





in a reduction of each data set to those peptides with their highest abundance in the bioactive 
region. Subsequently, sparse penalized linear regression modeling (elastic net27-28, including 
lasso29) is applied to correlate the relative abundance of post-filtered peptides and percent 
activity across library fractions in order to identify the specific peptide(s) causing bioactivity 
(Figure 3.2d). Because multiple peptides could jointly contribute to the bioactivity across a group 
of active fractions, a simple marginal correlation analysis strategy may produce inaccurate or 
spurious results for any individually contributing peptide. However, sparse penalized linear 
regression is able to account for this co-contribution to activity and results in more accurate 
identification of putative bioactive peptide species under the theoretical model. Elastic net 
regularization is an appropriate penalization specification as it elicits a sparse set of peptides 
contributing to bioactivity levels, helping to identify peptides most likely responsible for the 
corresponding bioactivities without strict limitation to a set number of peptides being selected. 
Identification of such a set facilitates prioritization of peptides for subsequent characterization 
and validation (Figure 3.2e). The elastic net path for fixed choice of quadratic penalty parameter 
can be obtained through a transformation of the predictor data and a subsequent application of 
the LARS algorithm30. Thus, in order to obtain a list of candidate compounds most likely to be 
contributing to the bioactivity, the order in which compounds' coefficients first obtain a nonzero 
value is tracked along the course of the algorithm, with coefficients that become nonzero earlier 
presumed to be better candidates for further investigation. 
3.3.6 Peptide Characterization  
Prioritized peptides are characterized via appropriate strategies depending on the target(s) of 
interest. While a top-down approach31 is used for detection of peptides of interest and may be 





LC-MS/MS analysis may be necessary to facilitate sequencing and identification of post-
translational modifications (PTMs). The accurate intact mass and MS/MS spectrum of the 
peptide species is obtained from the initial LC-MS/MS data collection. If necessary, further 
characterization is carried out utilizing the library fraction containing the most abundant amount 
of the peptide species of interest. Reduction and alkylation of cysteine residues is used to 
determine the number of disulfide bonds. Proteolysis is used to assess disulfide bond 
connectivity and possible cyclizations (e.g. cyclotides containing a single glutamic acid residue 
can be linearized through cleavage with endoproteinase GluC32). Paired Lys-C and Lys-N 
digestions can facilitate determination of termini by allowing identification with high confidence 
of b- and y- ions from the isobaric precursor ions33. Complementary tandem MS fragmentation 
via CID and ECD/ETD is used in combination to maximize peptide primary sequence 
determination and post-translational modification localization31, 34-35. De novo peptide 
sequencing will be facilitated using PEAKS software (Bioinformatics Solutions Inc.)36, 
supplemented with composition-based sequencing37,38 and homology-based database searches39 
to address plant species with limited sequencing information available. Structural mapping to 
delineate disulfide bond connectivity is carried out in combination with multi-enzyme 
digestions35, as appropriate, to dissect these key features that often confer bioactivity. 
3.3.7 Isolation and In Vitro/In Vivo Validation of Prioritized Bioactive Peptides  
Bioactive peptides that have been characterized are validated and their requisite bioactivity 
characterized. In vivo confirmation/validation of a bioactive peptide requires isolation to a high 
degree of purity to allow testing without interference from contaminating co-eluting compounds. 





pharmacological testing to determine if a peptide is a satisfactory lead compound that should be 
further evaluated. 
3.3.8 Platform Validation  
To validate the PepSAVI-MS pipeline, we demonstrate successful detection and 
identification of a known AMP from the botanical species Viola odorata. Viola odorata, 
commonly known as sweet violet, contains many cyclotides40 - including cycloviolacin O2 
(cyO2). CyO2 is a small, cysteine rich cyclotide comprised of 30 amino acids (MWmonoisotopic: 
3138.37 Da), which has been shown to have diverse activity against many Gram-negative 
bacteria (E. coli, K. pneumoniae, and P. aeruginosa)41, as well as several cancer cell lines42-43. 
Following the PepSAVI-MS pipeline as described above, V. odorata plants were grown, 
harvested, extracted, and crudely fractionated for creation of its peptide library. Using the known 
activities of cyO2 as a guide for assay selection, antibacterial bioassays were performed against 
E. coli (Figure 3.3a) and a panel of clinical strains representing the ESKAPE pathogens17 (Figure 
3.4). Each bioassay yielded robust bioactivity profiles unique to each microbe tested. Fractions 
containing the mass corresponding to cyO2 demonstrated growth inhibition for A. baumannii, P. 
aeruginosa and E. coli, but not for E. faecium, S. aureus, K. pneumoniae, or E. cloacae. As 
demonstrated previously44, the crude nature of SCX separation often results in group isolation of 
cyclotides (Figure 3.5). Hence, these fractions also contained additional cyclotides that have the 
potential to be contributing to the aforementioned activity. The majority of the remaining 
fractions did not show growth inhibition, indicating the source of activity was due to constituents 
within the fractions rather than the extract itself. To further demonstrate the broad applicability 
of the platform, V. odorata fractions were screened for activity against human breast (MDA-MB‐





profiles with increased cytotoxicity for these neoplastic cells in comparison to a non-cancerous 
human dermal fibroblast cell line (Figure 3.6). Viola odorata peptide library was also screened 
for growth inhibition against the filamentous fungus, Fusarium graminearum (PH-1), which 
similarly yielded a robust activity profile across the cyclotide-containing fractions (Figure 3.7). 
To determine which of the detected cyclotides could be contributing to the aforementioned 
bioactivity, V. odorata peptide library was subjected to LC-MS/MS and statistical analysis with 
the developed PepSAVI-MS software package. Retention time alignment and peak-picking of 
detected ions identified 6,258 unique features across V. odorata fractions 11 – 43. To validate 
our automated workflow for data processing, extracted ion chromatograms of cyO2 peptide were 
plotted for manual versus automated data extraction (Figure 3.3b). Extracted ion chromatograms 
show that cyO2 was detected at varying abundances across fractions 18 – 22 and validate the use 
of automation for data array generation. Following the known mass and charge properties of 
bioactive peptides, exported peptide ion data was filtered to include masses between 2 and 15 
kDa having charge states between +2 and +9 and eluting between 14 and 45 minutes. Remaining 
data was then binning using a 0.05 Da mass window with identical charge state requirements. 
Using the workflow informed criteria (described above) for data filtering and reduction with the 
bioactivity region specified as fractions 17 – 25, the number of possible candidates contributing 
to bioactivity was reduced to 225. This resulting list of candidate peptides was then subjected to 
statistical modeling of all bioactivity data sets, using the sparse penalized regression method, 
elastic net28. CyO2 from V. odorata was within the top 20 candidates for 2 of the 7 active species 
when modeled against the averaged bioactivity data. Furthermore, modeling individual 
bioactivity replicates with the requirement that any true component must be pulled out in at least 





set. CyO2 was characterized via a multi-step mass spectrometry-based approach (Figure 3.8) and 
these results are in agreement with previously published findings, thus confirming the identity of 
cyO240, 45. MS2 sequence coverage across the peptide allowed for distinction from another 
cyclotide, cyO9, present in sweet violet with the same intact mass as cyO2 and differing only by 
three residues. Only one other cyclotide corresponding to the intact mass of cyO17 appeared in 
the top 20 candidates after data reduction and statistical modeling of the E. coli bioactivity data 
set.  No other known cyclotides appeared in the top 20 candidates for any of the other bioactivity 
data sets. While this does not eliminate the possibility that other cyclotides could be contributing 
to the activity, our experiments suggest that cyO2 was the main contributor. To allow for greater 
access to the scientific community, the statistical analysis methods established for this platform 
have been developed into an R package, PepSAVIms, that is publically available through CRAN 
(https://cran.r-project.org/package=PepSAVIms). Included with this package are two vignettes 
providing an in-depth description of the functionality of the PepSAVI-MS pipeline package, as 
well as the specific bioinformatics implementation performed in this manuscript. 
To confirm that these bioassays are capable of detecting AMP activity at concentrations 
relevant for the observed activity, the minimum inhibitory concentration (MIC) of isolated cyO2 
against E. coli was determined. Using a broth microdilution assay in 96-well plate format, the 
MIC was determined to be 5 μM, which lies in between the previously reported MIC of 2.2 μM41 
and MIC50 of 6.8 µM13 for the same peptide on E. coli using different protocols. The 
concentration of cyO2 in the most abundant fraction (21) that killed or inhibited these strains was 
determined to be ~300 μM via area-under-the-curve integration of RPLC-MS peaks, which is in 





3.3.9 Novel Findings  
In addition to platform validation, unknown activities of cyO2 from V. odorata have been 
revealed in this study. Previously, it was demonstrated that cyO2 was active against a subset of 
the ESKAPE pathogens, including K. pneumoniae, and P. aeruginosa, and inactive against the 
tested Gram-positive bacteria, including S. aureus and E. faecium41. Results from our study are 
in agreement with the activity of cyO2 in the cyclotide fractions against E. coli and P. 
aeruginosa, and inactivity against E. faecium and S. aureus. However, we could not detect 
activity in these fractions against K. pneumoniae, which is likely due to high strain variability 
among this bacterial species46-47. Additionally, our assay detects strong activity of the cyclotide 
fractions against A. baumannii, of which there are no known reported studies of activity (Figure 
3.4). The MIC for the ESKAPE pathogen representing novel activity, A. baumannii, was 
determined to be 15 μM using isolated cyO2 and thus supports that cyO2 is the main contributor 
to the activity seen in these fractions. Throughout this study we have noticed variation in the 
sensitivity of peptidyl activity due to differences in media conditions and salt concentrations 
(Figure 3.9). We suspect that small differences even within different brands of the same medium 
could affect activity48-49 necessitating validation of new lots of media through testing of 
established fraction libraries to confirm consistency with previously collected bioactivity data. 
While our study shows some examples of changes in activity due to strain variability, the 
majority of findings remain consistent across different strains of the same species.  
Screening of V. odorata fractions against a panel of human cancer cell lines similarly 
demonstrates proof-of-principle, as well as an additional novel finding. In previous studies, cyO2 
has been shown to have anticancer activity against multiple breast and ovarian cancer cell lines42-





MB-231 breast cancer cell line, as well as the OVCAR-3 ovarian cancer cell line across fractions 
in which cyO2 was eluted. Additionally, this is the first demonstration of the ability of purified 
cyO2 to kill PC3 prostate cancer cells, with a determined IC50 of 6.6 μg/mL (2.1 μM). 
Furthermore, we demonstrate that the cyclotide fractions can kill the filamentous fungus F. 
graminearium and suspect the presence of an additional peptide(s) from V. odorata possessing 
antifungal capabilities (fractions 28 – 36). These studies not only highlight the wide applicability 
of this platform but also the capabilities of antimicrobial peptides as broad-spectrum 
therapeutics. 
3.4 Conclusion 
As demonstrated herein, the developed PepSAVI-MS pipeline is broad-spectrum, high-
throughput, and has the potential to expedite the search for new bioactive peptides from plants. 
Our platform overcomes many traditional limitations of drug discovery efforts through achieving 
increased efficiency by directly targeting and characterizing only those species contributing to 
the bioactivity. This may eliminate many laborious rounds of bioassay-guided fractionation or 
the need for characterization of all molecular species present, regardless of demonstrated 
activity. Furthermore, the developed platform is highly versatile as it is adaptable to any natural 
product source of peptides and can test against diverse physiological targets, including bacteria, 
fungi, viruses, protozoans, and cancer cells for which there is a developed bioassay. With this 
platform there is little bias towards high abundance compounds as the trend of activity values is 
more important than the raw abundance values. While the PepSAVI-MS pipeline has been 
developed to target cationic AMPs, the platform is adaptable to target other types of compounds 





for investigating purpose-guided natural product extracts with a new lens, and has the potential 

















Figure 3.1 Strong cation exchange elution profile for Viola odorata (black) at 280 nm with the 













Figure 3.2 Overall workflow for the PepSAVI-MS screening platform including (a) creation of 
peptide libraries through extraction and fractionation of crude extracts, (b) whole-cell bioactivity 
screening of peptide libraries against pathogen targets of interest, (c) LC-MS/MS analysis of 
active peptide libraries and (d) statistical modeling of LC-MS/MS datasets vs. active bioactivity 















Figure 3.3 V. odorata fractions (a) bioactivity vs. Escherichia coli with the growth-inhibition 
defined bioactivity region in blue where % activity indicates the decrease in bacterial aerobic 
metabolism quantified by resazurin reduction. (b) Aligned cyO2 elution profile with comparison 















Figure 3.4 Bioactivity data representing the novel activity of Viola odorata fractions vs. 
ESKAPE pathogens: (a) Enterococcus faecium (b) Staphylococcus aureus, (c) Klebsiella 
pneumoniae, (d) Acinetobacter baumannii, (e) Pseudomonas aeruginosa, and (f) Enterobacter 
cloacae. The growth inhibition-defined bioactivity region of cyO2 is depicted using blue bars for 




































Figure 3.5 Strong cation exchange elution profiles of other detected cyclotides across V. odorata 
fractions 11 – 47, where the color of the line indicates the charge state(s) in which each cyclotide 







Figure 3.6 V. odorata peptide library bioactivity profile against (a) breast (MDA-MB-231), (b) 
ovarian (OVCAR-3), and (c) prostate (PC3) cancer cell lines and (d) a non-cancerous human 
dermal fibroblast cell line. The cytotoxicity-defined bioactivity region of cyO2 against the given 


























Figure 3.7 V. odorata peptide library bioactivity profile against the filamentous fungus Fusarium 















Figure 3.8 Mass spectral characterization of cyO2 including accurate mass spectrum of (a) intact 
peptide, (b) reduced and alkylated peptide, (c) tryptic peptide, and (d) MS/MS of tryptic peptide 
for sequence determination with inset graphical fragment map indicating b- (green) and y- (red) 




















Figure 3.9 Difco MHB was used for all bacterial bioassays as shown with the V. odorata 
bioactivity against E. coli (a). When media from other vendors (e.g. Fluka) was used, bacterial 
growth was less robust, and some plant library fractions showed growth promotion indicating a 
nutritional deficiency in the MHB, supplied by those fractions, that interfered with accurate 
assessment of bioactivity (b). This effect was most pronounced with the Gram-positive 
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 Fungal Secretome Analysis via PepSAVI-MS: Identification of the Bioactive 
Peptide KP4 from Ustilago maydis 
*Reprinted with permission, from Kirkpatrick, C.L., Parsley, N.C., Bartges, T.E., Cooke, 
M.E., Evans, W.S., Heil, L.R., Smith, T.J., Hicks, L.M. Fungal Secretome Analysis via 




Fungi represent a diverse and versatile kingdom that has survived on earth for over 500 
million years1. While ~100,000 fungal species have been described to date, it is estimated that 5 
million fungal species could exist2. This vast and largely unexplored kingdom represents a rich 
source of untapped natural compounds that have been crucial for their survival. Used for defense, 
fungi produce a wide variety of molecules to leverage competitive advantage over invading 
microbial pathogens. Fungi-microbe interactions have led to the production of antimicrobial 
compounds that can be harnessed for human health, agricultural, and food safety applications3-4. 
Important among these are secreted small, cysteine rich antimicrobial peptides. 
Recent discoveries increasingly reveal bioactive peptides from a variety of sources to have 
substantial structural diversity and broad applications5-6. The antimicrobial peptide, copsin, from 
the basidiomycete Coprinopsis cinerea, was first discovered in 2014 and has potent activity 
against gram-positive bacteria including both the human pathogen Enterococcus faecium and the 
foodborne pathogen Listeria monocytogenes7. Additionally, there has been a growing interest in 
the agricultural use of bioactive peptides for crop protection, including transgenic expression in 
plants and topical application as biopesticides. Spear-T, a bioinsecticide derived from spider 





Importantly, unlike many currently used neonicotinoid-containing products, Spear-T has no 
adverse effects on bees or other beneficial insects, highlighting additional benefits of certain 
peptide-based agricultural products8. Fungi-microbe interactions have also inspired the use as 
these natural peptides in food safety applications, including the use of bacteriocins from lactic 
acid bacteria as starter cultures in food fermentation9.  
The promise of novel and effective mechanisms of action (MOAs) has revitalized peptide 
natural product discovery. In conjunction with methods aimed to expand knowledge of fungal 
genomes10-11, methods for rapid AMP identification of these species are required. Current 
methods employed for AMP identification include bioassay-guided approaches which rely on 
multiple rounds of fractionation, require large amounts of material, and often bias toward highly 
abundant or highly active compounds. Alternative genome mining approaches leverage the 
advantage of economical deep sequencing technologies but require knowledge of antimicrobial 
gene clusters or amino acid sequences a priori and offer no direct measure of bioactivity. As 
such, efficient and versatile methods are needed to screen potential AMPs against common and 
emerging pathogens. We developed PepSAVI-MS (Statistically guided bioactive peptides 
prioritized via mass spectrometry) to expedite discovery of bioactive peptides and validated this 
pipeline via identification and characterization of cycloviolacin O2 from the plant species Viola 
odorata (sweet violet)12. PepSAVI-MS utilizes selective extraction and fractionation of peptide 
source material, whole-cell bioactivity screening, and a statistics-guided mass spectrometry-
based approach for targeted identification of only putatively bioactive compounds. To expand 
the search for potent and effective AMPs, we now extend this pipeline to fungal secretomes, a 
rich source of AMPs with potentially novel MOAs created and refined by extreme inter- and 





Herein, we demonstrate expansion of PepSAVI-MS to fungal-sourced AMPs using the killer 
toxin KP4 from Ustilago maydis P4 as proof-of-principle. KP4 is a highly positively charged 
11.0 kDa peptide secreted by the corn smut fungus U. maydis when infected with the dsRNA P4 
virus. The host and virus have co-evolved such that the host is not affected by the dsRNA 
virally-encoded toxin but when secreted by the host the toxin kills all other strains of U. maydis, 
thus giving the strain a selective advantage over other U. maydis strains15-16. Two adaptations 
were required to demonstrate applicability of PepSAVI-MS for fungal secretome analysis: 1) an 
approach to harvest peptides secreted into the growth media replaced the extraction procedure 
and 2) the bioassay format was adapted to screen against relevant fungal species. Successful 
application of PepSAVI-MS to microbial secretomes establishes the utility of this pipeline for 
novel fungal bioactive peptide discovery. 
4.2 Materials and Methods  
4.2.1 Fungal Strains and Growth Conditions  
Ustilago maydis P4 and P6 strains were acquired from Robert Bozarth at Indiana State 
University and Jeremy Bruenn at Buffalo State, respectively. All U. maydis strains were grown 
in complete U. maydis media (UM media) consisting of 2.5% peptone (BD Difco), 1% dextrose 
(Sigma Aldrich), 0.15% ammonium nitrate (Sigma Aldrich), and 0.1% yeast extract (Sigma 
Aldrich). Four 5 mL starter cultures of U. maydis P4 were added to 2 L UM media and were 
grown to late-log phase at 25°C. Cells were removed by centrifugation (500 x g for 5 minutes) 
and the supernatant was collected. 
4.2.2 Secretome Peptide Harvesting  
The collected media was adjusted to a pH of 5.5 and stirred overnight with 140 mL of CM 





was gravity packed into a column and washed with two column volumes of 25 mM sodium 
acetate, pH 5.5, to remove unbound components. Peptides were eluted with 90 mL of 25 mM 
sodium acetate, pH 5.5, with 1 M NaCl, buffer exchanged into PBS (140 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4), pH 7.3, using 3 kDa spin concentration filters 
(Millipore) and concentrated 10X. 
4.2.3 Creation of Peptide Library via Crude SCX Fractionation  
Concentrated peptide secretome sample (420 μL) was subjected to a 40-minute SCX method 
using a PolySulfoethyl A column (100 mm x 4.6 mm, 3 m particles, PolyLC). A salt gradient 
was employed using a linear ramp of 5 mM ammonium formate, 20% acetonitrile, pH 2.7 to 500 
mM ammonium formate, 20% acetonitrile, pH 3.0. Fractions were collected in one-minute 
increments and desalted with three washes of 1.3 mL deionized water using a vacuum 
concentrator. 
4.2.4 Bioactivity Screening  
The susceptible culture selected for U. maydis P4 killing assays was U. maydis P6 (UMP6) a 
related Ustilago strain infected with the P6 virus. While also producing a deadly toxin of its own, 
KP6, these cells are susceptible to KP4. UMP6 fungal challenge cultures were grown for 5 days 
in 5-mL aliquots of complete UM media at 25°C with 240 rpm shaking. Soft agar was prepared 
fresh on the fifth day by the addition of 1.5% bacto agar (BD) to complete UM media and cooled 
in a water bath to 48°C for 1 hour. UMP6 cultures were added to the cooled agar at the ratio of 5 
mL fungus/250 mL agar. UMP6-infused agar was poured into 100 x 15 mL Petri dishes and once 
solidified, wells were carved into each plate using 10 μL pipette tips (4 wells/plate). UMP4 





compound addition, plates remained at room temperature until visible growth inhibition was 
present (~5 days). Radial zones of clearance were measured around the point of application.  
4.2.5 LC-MS/MS Analysis of Peptide Library 
The U. maydis P4 peptide library was analyzed via a nano-LC-ESI-MS/MS platform 
composed of a Waters nanoAcquity UPLC coupled to an AB Sciex TripleTOF 5600 QTOF mass 
spectrometer. Peptide fractions were diluted to ~0.2 μg/μL and acidified to 0.1 % formic acid.  
Five microliters of each sample were injected onto a trap column (NanoAcquity UPLC 2G-W/M 
Trap 5 μm Symmetry C18, 180 μm x 20 mm: Waters) before transfer to the analytical C18 
column (10k PSI, 100 Å, 1.8 μm, 75 μm x 250 mm: Waters). Peptide separation was carried out 
at a flow rate of 0.3 μL/minute using a linear ramp of 5 – 50 % mobile phase B (mobile phase A, 
0.1% formic acid; mobile phase B, 0.1% formic acid in acetonitrile) over 30 minutes. The MS 
was operated in positive ion, high sensitivity mode with the MS survey spectrum using a mass 
range of 350-1600 m/z in 250 ms and information dependent acquisition of MS/MS data, 87 ms 
per scan. For IDA MS/MS experiments, the first 20 features above 150 counts threshold and 
having a charge state of +2 to +5 were fragmented using rolling collision energy +5%. Each 
MS/MS experiment put the precursor m/z on an 8-second dynamic exclusion list. Auto 
calibration was performed every eight samples (8 h) to assure high mass accuracy in both MS 
and MS/MS acquisition. The mass spectrometry data have been deposited to the 
ProteomeXchange Consortium via the PRIDE 17 partner repository with the dataset identifier 
PXD006931. Deisotoped peak lists for each fraction were generated using Progenesis QI for 
Proteomics software (Nonlinear Dynamics, v.2.0). Automatic processing settings were used to 
align and peak pick ions across all runs. Identified features were quantified using AUC 





was exported as “peptide ion data” with the default parameters from Progenesis at the “Identify 
Peptides” stage in the software.  
4.2.6 Statistical Modeling  
Areas of interest in the bioactivity profile must be selected for subsequent data reduction and 
modeling. The bioactivity region for U. maydis P4 vs. U. maydis P6 was defined based on the 
observed bioactivity profile as fractions 27 - 32. Using the PepSAVI-MS software package 
(https://cran.r-project.org/package=PepSAVIms)12, background ions were eliminated through 
retention time (14 – 45 minutes), mass (2000 – 14000), and charge-state (2-10, inclusive) filters 
to reduce the data to potential compounds of interest. Retention time filters were selected to 
eliminate background ions, mass filters to select for the common mass range of bioactive 
peptides, and charge state filters to eliminate unwanted small molecules. Peak-picked data were 
binned and filtered using the previously established workflow-informed criteria12. Briefly, 
binning was performed with a 0.05 Da window of features with identical charge states and 
filtering required a maximum abundance inside the extended bioactivity area of interest (25 – 34) 
with <1% of that abundance outside of the chosen window.  The extended bioactivity region was 
defined as the region of bioactivity + 2 fractions on either side to account for the increased 
sensitivity of mass spectrometry (i.e. bioactive compounds may be present in those fractions at 
concentrations too low to detect bioactivity). All features required a minimum abundance of 
1000. All m/z species meeting these filtering criteria were modeled using the elastic net estimator 
with a quadratic penalty parameter specification of 0.001 to determine each species’ contribution 
to the observed overall bioactivity profile. The resulting list contains candidate compounds 
ranked in order of when they entered the model, such that the highest ranked compounds have 





4.2.7 KP4 Purification  
KP4 was purified as reported previously18-20. In brief, the toxin was isolated from the 
supernatant of the KP4 toxin expressing strains of U. maydis grown in complete U. maydis 
media for 7 to 10 days. Cells were removed by centrifugation at 10,000 x g for 30 minutes. The 
supernatant was stirred overnight with CM Sephadex C-25 resin (Amersham Biosciences) 
equilibrated with 25 mM sodium acetate, pH 5.5. The toxin was eluted with 1 M NaCl using a 
Pharmacia GradiFrac system. The eluent was concentrated using a Minitan II Ultrafiltration 
System (Millipore) with 1 kDa cutoff membranes and dialyzed against a 10 mM malonic acid, 
pH 6.0. KP4 was then purified using a high-resolution cation-exchange chromatography (Mono-
S; Amersham Biosciences) matrix attached to a fast-performance liquid chromatography system 
in the same buffer and using sodium chloride for elution. The toxin was further purified with size 
exclusion chromatography using an Amersham Biosciences Superdex-75 gel filtration column. 
Toxin activity was tested throughout the purification using killing-zone activity assays and purity 
was assessed using Homogenous 20 SDS gels on an Amersham Biosciences Phastgel system. 
Only a single band representing KP4 was observable when silver staining was used to observe 
the protein bands. 
4.2.8 KP4 Activity Validation  
Purified KP4 was tested in the agar diffusion assay as described above. A dilution series of 
KP4 starting at 9 μM and decreasing two-fold to 0.018 μM was used to determine the minimum 
inhibitory concentration. Erythromycin was used as a positive control at 100 μg/mL. Radii of 
inhibition were measured 4 days after application to UMP6-infused agar. Killing assays at all 





4.3 Results and Discussion 
4.3.1 Overview 
PepSAVI-MS implements a multipronged approach for bioactive peptide discovery that 
utilizes selective isolation and fractionation of peptides from source material, bioactivity 
screening, and mass spectrometry-based peptidomics for the identification of putative bioactive 
peptide targets. As PepSAVI-MS was originally demonstrated for expressed plant peptides, two 
minor adaptations were required to demonstrate applicability for fungal secretome analysis: 1) an 
approach to harvest peptides secreted into the growth media replaced the extraction procedure 
and 2) the bioassay format was adapted to screen against relevant fungal species (Figure 4.1).  
4.3.2 Creation of SCX Fractionated Libraries   
Secreted peptides are collected from the cell-free supernatant using weak cation exchange 
resin added directly to the media. The peptide-resin slurry was gently washed to remove 
unretained compounds, and then high salt was used to elute peptides/proteins. Then, SCX 
fractionation was used to create a UMP4 peptide library for bioactivity screening.  
4.3.3 Bioactivity Screening  
PepSAVI-MS is amenable to any developed bioassay and can be modified to accommodate 
any target pathogen. High-throughput 96-well microtiter-based assays for bacterial species were 
presented in the original demonstration of PepSAVI-MS12. However, this bioassay format is not 
amenable to fungal species that often fail to grow to high density and form fungal mats that 
interfere with accurate bioactivity measurements. For fungal species, traditional diffusion assays 
offer a tried-and-true format to obtain bioactivity data21. As such, agar-based diffusion assays 
were used to examine the activity of the U. maydis P4 SCX fraction library against a susceptible 





27-32) (Figure 4.2a). The crude nature of SCX allows for a single peptide to elute across 
multiple sequential fractions and thus span a wide bioactivity region. This characteristic is 
crucial for modeling of bioactivity and LC-MS data, as more points across the curve allow for 
increased confidence in matched profiles. The elution profile of a select subset of peptides across 
SCX fractions (obtained via LC-MS analysis) has been plotted in Figure 4.3. On average, any 
given peptide elutes across 2-3 sequential fractions in varying abundances, and peptides are 
eluting across all regions of the elution gradient. The combined elution and abundance profiles of 
each peptide create a unique fingerprint that allows for modeling with the bioactivity profile. 
4.3.4 MS Profiling, Data Reduction, and Statistical Modeling  
The U. maydis P4 SCX peptide library was subjected to LC-MS/MS analysis to obtain 
accurate mass and peptide abundance data for all constituents in the library. Peptide ion data 
reveals 17,473 features detected across the U. maydis P4 fraction set. Reduction of these features 
to those most-likely contributing to the bioactivity in each region narrowed the number of 
features to 19. This large reduction in features (99%) is unusual for what we typically see with 
other peptide libraries (~96% reduction in features12 and unpublished data). However, 
examination of fractions containing KP4 showed minimal peptidyl complexity in these particular 
fractions. Because KP4 is highly positively charged (10 basic residues), it retained on the SCX 
column much longer than other peptides and was detected in late eluting fractions. Statistical 
modeling using elastic net penalized linear regression of this filtered data set will still be useful 
to reveal a candidate list of compounds likely responsible for the bioactivity. When applied to the 
U. maydis data set, the four detected KP4 charge states (Figure 4.2b-c) meeting the filtering 
criteria ranked in the top 19 contributors [+7 (1st  rank), +8 (5th), +9 (6th), +10 (4th)] to the 





a given compound imparts a built-in compound redundancy that can help prioritize ranked 
species for downstream characterization and activity validation. The rank order of each charge 
state was independent of respective abundance, indicating PepSAVI-MS does not bias for highly 
abundant species. While not done in this case, collapsing charge states via protein deconvolution 
prior to modeling would allow an opportunity for more unique compounds to rank highly.  
4.3.5 Activity Validation with Purified KP4 
To confirm the activity of KP4, purified peptide was used in the agar diffusion-based assay 
against UMP6. KP4 was added to each well using a dilution series from 9 - 0.018 μM for 
minimum inhibitory concentration determination. After 4 days of incubation with KP6 infused 
agar, zones of inhibition were measured for each KP4 concentration. As seen in Figure 4.4, KP4 
displays potent, reproducible antifungal activity in a dose-dependent manner at concentrations as 
low as 0.07 μM.  No visible growth inhibition was observed at the two lowest KP4 
concentrations (35 and 18 nM). Interestingly, these results suggest that KP4 is more potent 
towards U. maydis P6 cells than towards U. maydis P2 cells (MIC: 0.33 μM22). KP4 is also 
reported to inhibit Arabidopsis root growth (ED50: 8 μM23) and expressed calcium channels 
(IC50:1.24 μM16) but to our knowledge, this is the lowest reported inhibitory activity of KP4.  
Successful application of PepSAVI-MS for fungal species demonstrates rapid and accurate 
identification of bioactive components from complex natural product secretomes and allows for 
focused downstream characterization and validation experiments on only the most promising 
species. Expansion of PepSAVI-MS to this historically rich source of bioactive molecules 
greatly enhances its capabilities and potential for novel bioactive peptide discovery. 
Furthermore, future implementations of PepSAVI-MS in combination with workflows that yield 





strategies using advanced algorithms such as RiPPquest24 or Pep2Path25 leverage 
complementarity of each and continue to expand capabilities.  
4.4 Conclusion 
PepSAVI-MS is a versatile and easily adaptable pipeline for natural product bioactive 
peptide discovery. Minor modifications to peptide extraction/collection and bioactivity assay 
format facilitate exploration of fungal secretomes, a rich source of bioactive peptides. Successful 
application of PepSAVI-MS to microbial secretomes, as demonstrated with U. maydis, opens the 
door to investigating fungal species with a new lens and may have translational applications 










Figure 4.1 Modifications to the originally proposed PepSAVI-MS pipeline for (a) collection of 
secreted peptides and (b) creation of fraction libraries and addition of each library to the adapted 
bioassay screen against relevant fungal species. Harvesting of secreted peptides includes large-
culture microbial growth, secretome isolation via centrifugation, addition of weak cation 
exchange peptide binding resin to cell-free supernatent, and elution of peptides off of the resin. 
Eluted peptides are then fractionated into libraries that are subject to bioactivity screening via 










Figure 4.2 U. maydis bioactivity and KP4 LC-MS analysis. (a) U. maydis fraction library 
bioactivity screening against UMP6 with (b) aligned elution profile for KP4 as determined via 














Figure 4.3 Elution profiles for a select subset of peptides (denoted by their mass and detected 
charge state) generated from exported peptide ion data. Distributions are plotted for a range of 
peptides across SCX fractions with relatively similar abundances for observation on the same 
scale; however, lower and higher abundance species display similar elution profiles. 
















Figure 4.4 Radii of inhibition observed through agar diffusion assays testing purified KP4 
against the challenge culture U. maydis P6. KP4 was added to each well in varying 
concentrations using a dilution series of KP4 starting at 9 μM and decreasing two-fold to 0.018 
μM. Erythromycin (Erm (+)) was used as a positive control at 100 μg/mL. Zones of inhibition 
were measured 4 days after application to UMP6-infused agar. Killing assays at all KP4 and Erm 
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5.1 Introduction 
Antibiotic-resistant infections are widespread, constantly evolving, and one of the biggest 
threats to global health (World Health Organization, 2017). While multidrug resistance (MDR) is 
occurring across an alarming number of bacterial species, among the most threatening MDR 
gram-positive organisms are enterococci. Though common commensal bacteria, enterococci are 
leading causes of hospital-acquired infections and are becoming highly antibiotic resistant1-2. 
Many species display intrinsic resistance to beta-lactam antibiotics, and further acquired 
resistance to tetracyclines, rifampin, and vancomycin, among others, severely limits therapeutic 
treatment options2-3. While the Enterococcus genus includes over 17 species, only a few have 
been shown to cause infections in humans. Enterococcus faecalis and Enterococcus faecium are 
the two most prevalent infectious species in humans and account for >90% of human isolates4. It 
is difficult, if not impossible in some cases, to treat these emerging and highly resistant 
enterococcal strains. It is crucial to develop analytical tools and novel therapeutic strategies to 
both characterize and treat these deadly strains. 
Many lactic acid bacteria, including enterococci, produce bacteriocins - small cyclic peptides 
capable of killing or inhibiting growth of related or similar species5-8. Bacteriocin production is 





niche for the producing strain5, 9-10. The enterococcal bacteriocin Bac-21 is encoded for on the 
sex pheromone-responsive conjugative plasmid pPD111. This class of plasmids constitutes a 
complex and highly efficient system used to both transfer genetic information and function as a 
regulator of bacterial virulence. To date, over 20 of these plasmids have been identified but only 
among enterococcal species12. The pPD1 plasmid is predicted to produce a mature, 70 amino 
acid bacteriocin, Bac-21, identical in nucleotide sequence to another well-characterized 
bacteriocin, AS-4811, 13. However, the active Bac-21 functional peptide has yet to be 
characterized. As demonstrated recently, the Bac-21 producing enterococcal strain is able to 
specifically decolonize antibiotic-resistant enterococci from the gastrointestinal tract14. This has 
major implications as a novel therapeutic strategy to overcome difficult-to-treat enterococcal 
infections, and by extension a similar approach could be used to combat other problematic gut 
organisms. While this highlights potential therapeutic implementation of bacteriocins, we posit 
that these peptide toxins represent a large and relatively untapped source of bioactive peptides 
that can be harnessed for drug discovery applications.  
PepSAVI-MS (Statistically guided bioactive peptides prioritized via mass spectrometry) was 
developed to expedite the search for botanical bioactive peptides while addressing limitations of 
bioassay-guided fractionation and genome mining approaches15. To enhance the search for 
potent and effective antimicrobial peptides (AMPs), we now extend this pipeline to bacterial 
secretomes, a rich source of AMPs with potentially novel mechanisms of action (MOAs) created 
and refined by extreme inter- and intra-species competition14, 16-17. Herein, we demonstrate 
expansion of PepSAVI-MS to bacterial-sourced AMPs using the bacteriocin Bac-21 from 
Enterococcus faecalis harboring the pPD1 plasmid. A robust agar diffusion assay approach was 





we experimentally validate the Bac-21 peptide sequence and post-translational processing for the 
first time. Successful application of PepSAVI-MS to bacterial secretomes is demonstrated with 
this representative species and establishes proof-of-principle for use in novel microbial bioactive 
peptide discovery. 
5.2 Materials and Methods  
5.2.1 Microbial Strains and Growth Conditions 
E. faecalis (CK135) harboring pPD114, 18-19 and E. faecium (JL282)18 strains were described 
previously. All Enterococcus strains were grown in Mueller Hinton Broth (MHB, BD Difco) and 
four 5 mL starter cultures of E. faecalis were added to 2 L of MHB and were grown to late-log 
phase at 37°C. Cells were removed by centrifugation (500 x g for 5 minutes) and the supernatant 
was collected. 
5.2.2 Creation of Peptide Libraries 
Secretome capture. The cell-free supernatant was adjusted to a pH of 5.5 and stirred 
overnight with 140 mL of CM Sephadex C-25 resin hydrated in 25 mM sodium acetate, pH 5.5. 
Slurry mixture was gravity packed into a column and washed with two column volumes of 25 
mM sodium acetate, pH 5.5, to remove unbound components. Peptides were eluted with 25 mM 
sodium acetate, pH 5.5, with 1 M NaCl and five 50 mL fractions were collected. Fractions were 
buffer exchanged into 5 mM ammonium formate, pH 2.7, using 3 kDa spin concentration filters 
(Millipore) and concentrated 10X.  
Strong cation exchange fractionation. Enterococcus crude fractions 2 and 3 (250 μL/fraction) 
were combined for strong cation exchange (SCX) fractionation via HPLC. The sample was 





particles, PolyLC). A salt gradient was employed using a linear ramp of 5 mM ammonium 
formate, 20% acetonitrile, pH 2.7 to 500 mM ammonium formate, 20% acetonitrile, pH 3.0. 
Fractions were collected in one-minute increments and desalted with three washes of 1.3 mL 
deionized water using a vacuum concentrator. 
5.2.3 Bioactivity Screening 
The susceptible culture selected for E. faecalis pPD1 killing assays, E. faecium JL282, was 
grown overnight in MHB. Soft agar was prepared for the agar diffusion assay by the addition of 
1.5% bacto agar (BD) to broth solutions. Microbes were added to warm (48°C), soft agar and 
poured into 100 x 15 mm culture dishes. Once solidified, wells were carved in the agar and 50 
L of each test fraction was added to a different well. Plates were incubated at 37°C until visible 
growth inhibition was present (~2 days). Radial zones of clearance were measured around the 
point of application. Bacterial assays were performed in duplicate.  
5.2.4 LC-MS/MS Analysis of Digested Peptide Library  
The E. faecalis peptide library was subject to reduction, alkylation, and Glu-C digestion 
(Staphylococcus aureus Protease V8) prior to LC-MS/MS analysis. Fractions were reduced using 
10 mM dithiothreitol (30 minutes, 45°C, 850 rpm) and subsequently alkylated with 100 mM 
iodoacetamide (15 minutes, 25°C, 850 rpm) prior to overnight digestion with Glu-C (37°C, 850 
rpm). E. faecalis digested fractions were cleaned up with Pierce C18 zip tips (Thermo Fisher 
Scientific) before subsequent LC-MS analysis. Peptide libraries were analyzed via a nano-LC-
ESI-MS/MS platform: Waters nanoAcquity UPLC coupled to an AB Sciex TripleTOF 5600. 
Peptide fractions were diluted to ~0.2 μg/μL and acidified to 0.1 % formic acid.  Five microliters 
of each sample were injected onto a trap column (NanoAcquity UPLC 2G-W/M Trap 5 μm 





PSI, 100 Å, 1.8 μm, 75 μm x 250 mm: Waters). Peptide separation was carried out at a flow rate 
of 0.3 μL/minute using a linear ramp of 5 – 50 % B (mobile phase A, 0.1% formic acid; mobile 
phase B, 0.1% formic acid in acetonitrile) over 30 minutes. The MS was operated in positive ion, 
high sensitivity mode with the MS survey spectrum using a mass range of 350-1600 m/z in 250 
ms and information dependent acquisition (IDA) of MS/MS data, 87 ms per scan. For IDA 
MS/MS experiments, the first 20 features above 150 counts threshold and having a charge state 
of +2 to +5 were fragmented using rolling collision energy +5%. Each MS/MS experiment put 
the precursor m/z on an 8-second dynamic exclusion list. Auto calibration was performed every 
eight samples (8 h) to assure high mass accuracy in both MS and MS/MS acquisition. The mass 
spectrometry data have been deposited to the ProteomeXchange Consortium via the PRIDE20 
partner repository with the dataset identifier PXD009003 and 10.6019/PDX009003. Deisotoped 
peak lists for each fraction were generated using Progenesis QI for Proteomics software 
(Nonlinear Dynamics, v.2.0). Automatic processing settings were used to align all runs using 
fraction 37 as the reference and peak picking ions across the entire digested library. Identified 
features were quantified using AUC integration of survey scan data based on the summed 
intensity of each deisotoped feature. Data was exported as “peptide ion data” with the default 
parameters from Progenesis at the “Identify Peptides” stage in the software.  
5.2.5 Database Searching of Digested Peptide Library 
Identification and location of Bac-21 Glu-C digested peptides was determined using Mascot 
(v.2.5.0; Matrix Science, http://www.matrixscience.com/). While the mature Bac-21 peptide has 
until now not been physically detected or molecularly characterized, its identity in nucleotide 
sequence to another well-characterized bacteriocin, AS-48, was used to predict its protein 





database (68,530 entries; accessed February, 2017) appended with the predicted peptide 
sequence of Bac-21. Searches of MS/MS data used a Glu-C protease specificity allowing two 
missed cleavages, peptide/fragment mass tolerances of 10 ppm/0.08 Da, a fixed modification of 
carbamidomethylation of cysteine residues, and variable modifications of acetylation at the 
protein N-terminus and oxidation at methionine.  
5.2.6 Statistical Modeling of Digested Peptide Library 
Areas of interest in the bioactivity profile were selected for subsequent data reduction and 
modeling. The bioactivity region for this dataset was defined as fractions 35 - 39. Using the 
PepSAVI-MS software package (https://cran.r-project.org/package=PepSAVIms)15, background 
ions were eliminated through retention time (14 – 45 minutes), mass (200 – 1600 for E. faecalis 
digest), and charge-state (1-10, inclusive) filters to reduce the data to potential compounds of 
interest. For intact peptide libraries, singly charged species excluded to further select for highly 
positively charged bioactive peptides, however, these compounds are allowed to remain in the 
model for library digests. Retention time filters were selected to eliminate background ions, mass 
filters to select for the common mass range of bioactive peptides, and charge state filters to 
eliminate unwanted small molecules. Peak-picked data were binned and filtered using the 
previously established workflow-informed criteria 15. Briefly, binning was performed with a 0.05 
Da window of features with identical charge states and filtering required a maximum abundance 
inside the bioactivity area of interest (fractions 35 – 39) with <1% of that abundance outside of 
the chosen window.  All features required minimum abundance of 100. All m/z species meeting 
these filtering criteria were modeled using the elastic net estimator with a quadratic penalty 
parameter specification of 0.001 to determine each species’ contribution to the observed overall 





entered the model, such that the highest ranked compounds have the greatest likelihood of 
contributing to the bioactivity. 
5.2.7 LC-MS Analysis of Intact Peptide Library  
A select subset of fractions (32-42) including and surrounding the observed bioactivity 
region were subject to direct infusion on a Thermo Orbitrap Q Exactive HF-X for intact mass 
analysis.  Fractions were prepared in 50% water, 50% methanol, and 0.1% formic acid with no 
dilution from the original library concentration, and were injected at a flow rate of 5 μL/minute. 
The mass spectrometer was operated at a resolving power of 120,000, positive ion mode, with 
1000 – 2000 m/z range, and collecting 100 scans/sample. Progenesis QI for proteomics was used 
to generate a deisotoped peak list for intact samples, as described above.  
5.2.8 Statistical Modeling of Intact Peptide Library 
Exported peptide ion data for the intact library was processed as described for the digested 
peptide library with the following adjustments: (1) binning was performed using a mass range of 
2000 – 10,000 Da to account for intact peptides and (2) a minimum intensity of 10,000,000 was 
required in the filtering stage to account for microscale direct infusion intensities. Exported 
peptide ion data contained 240 unique features, which were reduced to 177 after binning and 24 
after filtering. The remaining 24 compounds entered to penalized linear regression model to 
determine the top 20 compounds most-likely contributing to the observed bioactivity profile. 
5.2.9 Bac-21 Top-down Characterization 
For top-down analysis, the most abundant Bac-21 containing E. faecalis pPD1 fraction was 
analyzed on an LTQ-Orbitrap XL platform (Thermo Fisher Scientific). The sample was subject 
to direct infusion utilizing a 35 micron ESI emitter (New Objective Inc.). Samples were diluted 





injected at a flow rate of 0.5 μL/minute. The mass spectrometer was operated at a resolving 
power of 30,000 at 400 m/z, positive ion mode, with 900 – 2000 m/z range. The spectra were 
deconvoluted using the AutoXtract algorithm in Protein Deconvolution 4.0 (Thermo Fisher 
Scientific). CID fragmentation was performed on the +6 Bac-21 charge state (1192 m/z) with a 
collisional energy of 35 V and 600 – 2000 m/z range. Data analysis was accomplished using a 
custom informatics search engine adapted from Plymire et al.21. The candidate sequences were 
tested against the fragmentation data at 15 ppm mass tolerance. The searches tested fragments 
against every possible initial cleavage event position for the cyclic peptide tested. Outputs report 
the number of fragment hits, rank initial cleavage sites by a Poisson-based p-score22, and output 
maps associated with each position. 
5.3 Results and Discussion 
5.3.1 Overview 
PepSAVI-MS implements a multipronged approach for bioactive peptide discovery that 
utilizes selective extraction and fractionation of peptides from source material, bioactivity 
screening, and mass spectrometry-based peptidomics for the identification of putative bioactive 
peptide targets. PepSAVI-MS was originally established for constitutively-expressed peptides 
from botanical-sourced species and was recently validated for fungal secretome capture23. Now, 
we extend this pipeline to capture secreted peptides from bacterial sources (Figure 5.1). 
Additionally, we demonstrate that digestion of source libraries post-bioassay is an optional step 
for more facile detection of very large bioactive species (peptides/proteins) that may be difficult 
to detect intact depending on available LC-MS/MS hardware. Expansion of PepSAVI-MS to 
bacterial secretomes using digested peptide libraries highlights the versatility and wide 





in conjunction with high resolution, high mass accuracy mass spectrometry we are able to detect 
and characterize the active, mature Bac-21 peptide for the first time. 
5.3.2 Secretome Capture and Peptide Library Generation  
Dynamic microbe-microbe interactions and environmental competitive advantage are 
mediated by an array of secreted host-defense peptides. Although created for survival, the innate 
bioactivity of these peptides poses a promising source of molecules to exploit for drug discovery. 
As such, we have expanded PepSAVI-MS to capture potential bioactive components from the 
microbial secretome. Secreted peptides are collected from the cell-free supernatant using weak 
cation exchange (WCX) resin added directly to the media and eluted in bulk using high salt. As 
the majority of bioactive peptides have been found to be highly positively charged, these 
peptides will be retained using WCX resin. However, other resin chemistries can easily be 
substituted at this stage for capture of a specific class of bioactive peptides with unique chemical 
properties. Concentrated elutions are then combined and crudely fractionated using SCX for 
peptide library creation.  
5.3.3 Bioactivity Screening 
PepSAVI-MS is amenable to a variety of bioassay formats and can be modified to 
accommodate any target pathogen. High-throughput microtiter-based assays and agar diffusion-
based assays have been previously demonstrated with PepSAVI-MS15, 23. While many bacterial 
species bode well in high throughput 96-well assays (as presented in the original implementation 
of the PepSAVI-MS pipeline), this format is not amenable to some bacterial species that fail to 
grow to high density (e.g. < 0.5 OD) in low volume formats. This was the case with enterococcal 
cultures in Mueller Hinton Broth (MHB) and as such, agar-based diffusion assays (originally 





against its respective susceptible culture, E. faecium. The E. faecalis pPD1 peptide library shows 
strong activity against E. faecium, with measurable zones of inhibition present in fractions 35 – 
39 (Figure 5.2). The bioactivity region is a discrete and well-defined profile spanning five 
sequential fractions with varying zones of inhibition. This representative profile is ideal for 
PepSAVI-MS as the bioactive peptide responsible for the activity will have five paired 
bioactivity and LC-MS abundance data points to facilitate statistics and modeling. 
5.3.4 MS Profiling of E. faecalis pPD1 Peptide Library 
The peptide library is subjected to LC-MS/MS analysis to obtain accurate mass and peptide 
abundance data for all constituents. PepSAVI-MS was originally demonstrated with top-down, 
intact peptidome libraries. However, an optional digestion prior to LC-MS/MS analysis may 
facilitate detection of target peptides in a manner similar to the bottom-up Activity-Correlated 
Quantitative Proteomics Platform (ACPP) used to identify enzymes with targeted reaction 
specificity24. This approach is particularly useful for larger peptides with low charge density or 
poor ionization efficiency, or for investigations implementing resolving power-limited mass 
spectrometry hardware. In such cases, database searching against the same or highly related 
microbial species can be used to determine the peptide constituents within each fraction and the 
proteolytic peptide(s) can be used for quantification and modeling via PepSAVI-MS. Proteolytic 
peptides highly ranked as putatively bioactive can be used as a proxy for the intact peptide 
present in each fraction. This digestion step is demonstrated herein for the E. faecalis peptide 
library, and is validated through comparison to the original top-down intact analysis approach. 
Positively charged residues (i.e. Arg, Lys) are frequently occurring in most bioactive peptides 
and would be cleaved by trypsin into many short peptides that elude LC-MS detection. Thus, 





proteolytic processing in order to obtain longer peptides with a higher probability to achieve 
increased protein coverage. 
Peptide ion data reveals 10,132 features detected across Glu-C digested fractions 30-45 for 
the E. faecalis pPD1 library. This peptide ion data is used for both unbiased data reduction and 
statistical modeling with unassigned m/z ratios and database searching using Mascot for 
identification. For unbiased data reduction and statistical modeling, peptide ion data is first 
reduced to features most-likely contributing to the bioactivity in each region through mass, 
retention time, and elution profile mapping. When applied to the E. faecalis pPD1 data set, this 
reduction identified 3,727 unique m/z ratios that were further filtered to 23 compounds with 
abundance profiles spanning the bioactivity region. Statistical modeling using elastic net 
penalized linear regression of this filtered data set reveals a candidate list of compounds likely 
responsible for the bioactivity region. After modeling, a list of the top 20 m/z’s likely 
contributing to the observed bioactivity is generated (Figure 5.3). Then, comparison of the top 20 
contributing m/z ratios with the Mascot output for the entire dataset facilitates the assignment of 
top contributors. In this case, the 2nd, 4th and 5th top contributors (m/z ratios 1555.86, 540.32 and 
360.55) correspond to the +2 and +3 charge states of two Bac-21 Glu-C peptides: 
FGIPAAVAGTVLNVVE (+2) and SIKAYLKKE (+2, +3) (Figures 5.3 and 5.4). Glu-C 
digestion of the E. faecalis pPD1 library yielded three of the four possible Bac-21 peptides, 
providing 58% sequence coverage of the mature peptide. While three peptides were detected 
using Mascot, only two (FGIPAAVAGTVLNVVE and SIKAYLKKE) ranked in the top 20 
compound list after statistical modeling. It is likely that low abundance and incomplete digestion 





digestion efficiency may increase the number of identified and ranked proteolytic peptides, 
increasing confidence in bioactive peptide identification in future experiments.  
Analysis of intact E. faecalis pPD1 peptide library reveals 240 unique features across 
fractions 32-42. Binning and filtering parameters were adjusted for the increased size of intact 
peptides, but was modeled against the same bioactivity data as the Glu-C digested peptide 
library. The resulting top 20 list after binning, filtering, and modeling featured all three of the 
detected Bac-21 charge states, ranking 2nd (+6), 14th (+4) and 17th (+5).  
5.3.5 Characterization of Intact Bac-21  
While evidence of E. faecalis Bac-21 has been demonstrated through bioactivity14, Bac-21 
has never been molecularly characterized. Hence, the most abundant Bac-21 containing library 
fraction was characterized pre-digestion (i.e. intact) using direct infusion, high resolution mass 
spectrometry in combination with collision induced dissociation for increased sensitivity and 
accurate mass detection. As intact Bac-21 is a cyclic peptide, two fragmentation events must 
occur to produce fragment ions via MS/MS. The initial fragmentation is a ring opening event that 
can occur at any amino acid residue but will produce the same precursor mass. The second 
fragmentation event produces the classical b- and y- ion series typically associated with CID. 
While the initial fragmentation event produces identical linear masses independent of the initial 
cleavage point, the b- and y-ions generated from each of these linear sequences will be unique to 
the initial cleavage point. As such, fragmentation of cyclic peptides exponentially increases the 
number of possible fragment ions produced from a single peptide. While providing a wealth of 
information to use for peptide sequencing, interpretation of these MS/MS spectra is often 
complex and confident fragment assignment is often ambiguous in many cases. Automatic 





search engine21 was used in this case. As such, the accurate intact mass of Bac-21 was 
determined to be 7145.071-0 Da (7145.072-0 Da theoretical; 0.3 ppm mass accuracy) with 70% 
sequence coverage obtained via CID fragmentation (Figure 5.5). These results indicate that Bac-
21 is identical in both primary protein sequence and post-translational processing (head-to-tail 
cyclization) to the known bacteriocin AS-4811, 13. Unsurprisingly, the most frequent initial 
fragmentation event occurred at the only proline residue (denoted as the 8th amino acid) in Bac-
21.  The next, most frequent initial fragmentation events occurred at 11th, 12th, and 36th amino 
acid residues of  V, A, and G, respectively, and likely indicate structural weak points in the 
folded peptide. 
5.4 Conclusion 
PepSAVI-MS is a highly versatile and easily adaptable pipeline for natural product bioactive 
peptide discovery. Successful application of PepSAVI-MS for bacterial secretome capture 
demonstrates rapid and accurate identification of bioactive components from complex natural 
product secretomes and allows for focused downstream characterization and validation 
experiments on only the most promising species. Expansion of PepSAVI-MS to this historically 
rich source of bioactive molecules greatly enhances its capabilities and potential for novel 
bioactive peptide discovery. Furthermore, minor modifications to the original pipeline, including 
the use of agar diffusion assays for recalcitrant bacterial species and digestion of peptide libraries 
for sequenced organisms, facilitates exploration of bacterial secretomes and expands the 
applicability of PepSAVI-MS to data acquired with lower resolution mass spectrometry 
hardware. Successful application of PepSAVI-MS to microbial secretomes, as demonstrated with 
E. faecalis, opens the door to investigating microbial species with a new lens and stands to have 







Figure 5.1 Overall workflow for PepSAVI-MS application to bacterial secretomes using digested 
peptide libraries. The developed workflow is amenable to large-scale microbial culture growth to 
produce secreted peptides in sufficient quantities for downstream analysis. Secreted peptides are 
captured with cation exchange resin and crudely fractionated for creation of each peptide library.  
Peptide libraries are subject to LC-MS analysis and bioactivity screening, and generated data sets 








Figure 5.2 E. faecalis pPD1 SCX fraction library bioactivity against E. faecium JL282. Assays 








Figure 5.3 PepSAVI-MS statistical modeling summary, including the list of the top 20 
compounds, denoted by rank, m/z ratio and charge state, to exit the PepSAVI-MS statistical 
model for the digested peptide library. The first compound can be considered the most likely 
compound contributing to the observed bioactivity, with the likelihood decreasing down the rank 








Figure 5.4 Representative MS/MS spectra generated from CID fragmentation of Bac-21 Glu-C 
peptides on a TripleTOF 5600 Q-TOF platform. Peptide fragment maps used for Mascot 







Figure 5.5 (a) Mass spectrum of intact Bac-21 (LTQ-Orbitrap XL). (b) Deconvoluted and 
annotated CID spectrum of 1192 m/z (Bac-21 +6 charge state). Fragmentation coverage was 
determined using the four most prevalent linear sequences, denoted by the number of the starting 
amino acid from the initial cyclic sequence. B- and y-ions are labeled using traditional 
nomenclature with the number of the starting amino acid residue in parenthesis.  Full linear 
sequences and ion coverage are provided below for clarity. Ions denoted with * indicate that 
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6.1 Introduction 
Plants of the Amaranthus spp. have long been known as natural remedies for chronic 
illnesses. Amaranthus extracts have been used across Southern and Eastern Asia to treat 
conditions including urinary infections, diarrhea, pain, respiratory disorders, and diabetes1-3. 
Now, with the growing antimicrobial resistance concern, these ancient remedies are receiving 
increased attention a viable source of therapeutic compounds. Due to this reinvigorated effort, 
recent studies have revealed anticancer, antiviral, hepatoprotective, neuroprotective, 
cardioprotective, and antidiabetic activities of Amaranthus1. 
Recent research exploring Amaranthus has utilized virtually all parts of the plant under 
different extraction conditions and testing for different antioxidant and pharmacological 
activities1. However, the majority of these studies implemented organic extractions and largely 
focused on small molecule constituents. To our knowledge, most of the reported proteinaceous 
activity of Amaranthus is from the seeds of various species4-8. Activity detected from the seeds in 
these studies includes anticancer and antihypertenstion bioactivity. While exciting, we posit that 
peptidyl activity across Amaranthus spp. remains underexplored, especially within aerial tissues. 
As such, we apply our bioactive peptide discovery pipeline, PepSAVI-MS, to Amaranthus 





Amaranthus tricolor, commonly known as edible amaranth, Joseph’s coat, or red spinach, is 
of particular interest due to its history in traditional medicine. The whole plant has been 
consumed for centuries in Indian culture to promote general overall health, and the roots have 
been used to control bleeding9. Recent research has revealed the leaves of A. tricolor to be anti-
nociceptive, antidiabetic, hepatoprotective, gastroprotective, neuroprotective and anti-
inflammatory10-16. A. tricolor leaf powder has even been shown to prevent post-menopause 
complications, highlighting antioxidant activity of these tissues17. While extremely diverse  
activity has been identified, antimicrobial action of this particular species is largely unexplored. 
Furthermore, the activity of A. tricolor extracts has been attributed to the extract as a whole (i.e. 
specific active compound not identified) or attributed to small molecules. As such, innovative 
tools that specifically target bioactive peptide discovery are required to probe this unique subset 
of compounds.  
The PepSAVI-MS pipeline has been developed to expedite the search for natural product 
bioactive peptides and has been validated for use in plants through the identification of the 
bioactive peptide cyO2 from Viola odorata18. Herein, we explore antimicrobial activity from the 
leaves of A. tricolor using PepSAVI-MS. Bioactivity results indicate strong activity against the 
gram-negative bacterium Escherichia coli. This activity is retained through both SCX and 
reversed phase fractionation, indicating high stability of the target peptide. Using the 
PepSAVIms statistical analysis package, the top 20 candidates most-likely contributing to the 
observed bioactivity have been identified. Further work is being performed to identify the 
specific bioactive component, and to isolate or synthesize the active compound. The purified 





against a full panel of gram-negative and gram-positive bacteria to assess full bioactivity 
potential. 
6.2 Materials and Methods 
6.2.1 Plant Growth and Harvest 
Amaranthus tricolor seeds purchased from Strictly Medicinal Seeds (formerly Horizon 
Herbs; Williams, OR) were grown to mature rosette stage (~8 weeks) (Figure 6.1). 
Approximately 100 seeds were planted in nutrient-rich soil and grown under controlled 
temperature (63.5 - 68.5°F) and light cycle (14-hr light) conditions. Due to the high germination 
rate, seedlings were thinned after two weeks to allow ample space and nutrients to for growth. 
Following an additional two weeks, remaining healthy seedlings were transplanted into 
individual pots. Aerial tissue was taken from ~20 healthy, mature plants (equivalent to ~140 g of 
powdered material), harvested, immediately flash frozen with liquid nitrogen, and stored at -
80°C until subsequent extraction.  
6.2.2 Peptide Library Creation 
Peptide Extraction. Frozen tissue (100 g) was ground under liquid nitrogen using a mortar 
and pestle and aqueously extracted in 300 mL of 10% acetic acid with protease inhibitors 
(Roche, 6 tablets) with stirring for 4 hours at 4°C. Insoluble material was pelleted by 
centrifugation and filtered using a 0.45 μm Stericup filtration (Millipore). Protein concentration 
filters (30 kDa, Millipore) were used to remove high molecular weight species followed by 
dialysis (0.1 – 1 kDa cutoff; SpectrumLabs) into 5 mM ammonium formate pH 2.7 to eliminate 
small molecules. The sample was concentrated via vacuum centrifugation to 4 mL to generate 





HPLC Fractionation. Four crude extracts were combined and further concentrated to 420 μL 
to create a 4x concentrated crude extract. The concentrated extract was subjected to a 47-minute 
SCX method using a PolySulfoethylA column (100 x 4.6 mm, 3 μm particles, PolyLC). A salt 
gradient was employed using a linear ramp from 5 mM ammonium formate, 20% acetonitrile, 
pH 2.7 to 500 mM ammonium formate, 20% acetonitrile, pH 3.0. Fractions were collected across 
the 47-minute run in one-minute intervals and desalted with three washes of 1.3 mL water using 
a vacuum concentrator. Peptide libraries were stored in water (250 μL/fraction) at 4°C until 
bioactivity assay.  
6.2.3 Bioactivity Screening 
Escherichia coli (25922) was obtained through ATCC and the ESKAPE pathogen strains are 
clinical isolates that belong to a collection acquired by the Shaw Lab [Staphylococcus aureus 
(635), Klebsiella pneumoniae (1433), Acinetobacter baumannii (1403)]19. Bacterial starter 
cultures were grown from an isolated colony on a freshly streaked agar plate in 5 mL of Mueller 
Hinton Broth (MHB). Overnight cultures were diluted to 0.1 OD in the morning and grown for 
one additional hour. After, a master mix was prepared by combining 4 mL of 1x MHB, 2 mL of 
2x MHB, and 2 mL of bacterial culture, such that the plating OD was ~0.1. All assays were 
performed in 96-well microtiter plates by adding 10 μL of peptide fraction to 40 μL master mix. 
Positive (ampicillin, 100 μg/mL) and negative (water) controls were added to each plate. The 
prepared plates were incubated (37°C, 275 rpm shaking) for 4 hours depending before the 
addition of 1 μL resazurin (50 mM) to each well. After one additional hour of shaking and 
incubation, a fluorescence read of 544 nm (ex) and 590 nm (em) was collected to measure 





6.2.4 Reversed Phase Separation 
As the initial SCX peptide library displayed activity in an unusually large number of 
fractions, a second round of fractionation was used to further separate and probe individual 
regions of activity. Active SCX fractions 27, 28, and 29 were combined (~150 μL/fraction) for 
further reversed phase fractionation. 420 μL of combined sample was subject to reversed phase 
fraction on a Shimadzu HPLC using a Phenomenex Jupiter C18 column (150 x 4.6 mm, 5 μm, 
300 Å). Aqueous (95% water/5% acetonitrile/0.1% TFA) and organic (100% acetonitrile/0.1% 
TFA) solutions were used for mobile phase A and B, respectively. A two-step organic gradient 
was applied, and 1-minute fractions were collected across the gradient. Fractions were dried 
down and resuspended in 25 μL of water. Reversed phase (RP) fractions were subject to 
bioactivity screening as described above, with the exception of being in conducted in duplicate 
instead of triplicate to conserve material. 
6.2.5 LC-MS/MS Analysis 
A. tricolor SCX and RP peptide libraries (fractions 11-40 and 11-35, respectively) were 
analyzed on a nano-LC-ESI-MS/MS platform composed of a Waters nanoAcquity UPLC 
coupled to an AB Sciex TripleTOF 5600 QTOF mass spectrometer. Peptide fractions were 
diluted to ~0.2 μg/μL and acidified to 0.1 % formic acid. Five microliters of each sample were 
injected onto a trap column (NanoAcquity UPLC 2G-W/M Trap 5 μm Symmetry C18, 180 μm x 
20 mm: Waters) before transfer to the analytical C18 column (10k PSI, 100 Å, 1.8 μm, 75 μm x 
250 mm: Waters). Peptide separation was carried out at a flow rate of 0.3 μL/minute using a 
linear ramp of 5 – 50 % mobile phase B (mobile phase A, 0.1% formic acid; mobile phase B, 
0.1% formic acid in acetonitrile) over 30 minutes. The MS was operated in positive ion, high 





and information dependent acquisition of MS/MS data, 87 ms per scan. For IDA MS/MS 
experiments, the first 20 features above 150 counts threshold and having a charge state of +2 to 
+5 were fragmented using rolling collision energy +5%. Each MS/MS experiment put the 
precursor m/z on an 8-second dynamic exclusion list. Auto calibration was performed every eight 
samples (8 h) to assure high mass accuracy in both MS and MS/MS acquisition. Deisotoped peak 
lists for each library were generated using Progenesis QI for Proteomics software (Nonlinear 
Dynamics, v.2.0). Automatic processing settings were used to align and peak pick ions across all 
runs, using fractions 28 and 17 as the reference runs for the SCX and RP libraries, respectively. 
Additionally, a minimum peak with of 0.1 minutes was applied. Identified features were 
quantified using AUC integration of survey scan data based on the summed intensity of each 
deisotoped feature. Data was exported as “peptide ion data” with the default parameters from 
Progenesis at the “Identify Peptides” stage in the software. 
6.2.6 Statistical Modeling of Reversed Phase Fractions 
The bioactivity region for A. tricolor vs. E. coli was defined based on the observed 
bioactivity profile as fractions 16 - 19. Using the PepSAVI-MS software package (https://cran.r-
project.org/package=PepSAVIms)18, background ions were eliminated through retention time 
(14 – 45 minutes), mass (1000 – 10000 Da), and charge-state (2-10, inclusive) filters to reduce 
the data to potential compounds of interest. Peak-picked data were binned and filtered using the 
previously established workflow-informed criteria18. Briefly, binning was performed with a 0.05 
Da window of features with identical charge states and filtering required a maximum abundance 
inside the extended bioactivity area of interest (16 – 19) with <10% of that abundance outside of 
the chosen window. All features required a minimum abundance of 100. All m/z species meeting 





parameter specification of 0.001 to determine each species’ contribution to the observed overall 
bioactivity profile. The resulting list contains candidate compounds ranked in order of when they 
entered the model, such that the highest ranked compounds have the greatest likelihood to be 
contributing to the bioactivity. 
6.2.7 Peptide Characterization 
The most promising peptide target from the top 20 modeled species is undergoing subsequent 
characterization for primary sequence determination. The A. tricolor SCX fraction with the 
highest abundance of target peptide was split into three samples that were reduced using 10 mM 
dithiothreitol (30 minutes, 45°C, 850 rpm) and alkylated with 100 mM iodoacetamide (15 
minutes, 25°C, 850 rpm). One aliquot was quenched and frozen at this point, and the other two 
were subject to overnight digestion with either trypsin or Glu-C (37°C, 850 rpm). A. tricolor 
digested fractions were cleaned up with Pierce C18 zip tips (Thermo Fisher Scientific) before 
subsequent LC-MS analysis. The reduced and alkylated sample was used to identify predicted 
mass shifts associated with disulfide bonds. The digested samples were searched using Mascot 
(v.2.5.0; Matrix Science, http://www.matrixscience.com/) for protein identification. Database 
searching was performed using the A. tricolor database generated from transcriptomic data 
(21,758 entries; accessed November, 2017). Searches of MS/MS data used either trypsin or Glu-
C protease specificity allowing two missed cleavages, peptide/fragment mass tolerances of 10 
ppm/0.08 Da, a fixed modification of carbamidomethylation of cysteine residues, and variable 





6.3 Results and Discussion 
6.3.1 Overview  
Amaranthus tricolor has long been known for its role as a traditional medicinal species with 
a wealth of healing capabilities. Broad spectrum activity of this species has largely been 
attributed to small molecules ranging from phenolic compounds to betalains4-8, however activity 
due to peptidyl components remains unexplored. Here, we use PepSAVI-MS to probe the 
bioactive peptide pool from A. tricolor and identify novel lead compounds for identification and 
activity validation.  
6.3.2 Plant Growth and Peptide Extraction 
A. tricolor seeds were grown under standard greenhouse conditions for 8 weeks until ample 
aerial tissue was available. Healthy leaves were harvested from the plants, packaged in 
aluminum foil packets, and flash frozen under liquid nitrogen. Peptide extraction was performed 
using 100 g of ground aerial tissue extracted into an aqueous buffer, as described by Kirkpatrick 
et al18. Size exclusion filters were used to select for peptide-sized compounds (1-10 kDa), and 
sample was concentrated for creation of the A. tricolor crude extract.  
6.3.3 Peptide Library Creation 
The A. tricolor crude extract was subject to strong cation exchange fractionation, where 
positively charged bioactive peptides retain on the column until elution with a high salt gradient. 
As shown in Figure 6.2a, the 280 nm SCX trace for A. tricolor crude extract contains high levels 
of unretained compounds eluting before the salt gradient is applied. These compounds are likely 
small, negatively charged or neutral molecules common in plant extracts. As activity of this 
subset of compounds has been thoroughly studied and reported in literature, the focus of this 





are collected across the optimized 47-minute run, and once desalted comprise the SCX peptide 
library for downstream analysis.  
6.3.4 Bioactivity Screening: SCX Peptide Library 
A. tricolor SCX peptide library was subject to preliminary bioactivity screening versus E. 
coli. Each peptide fraction was incubated with actively growing E. coli cells, in triplicate, and 
after 4 hours of incubation the number of remaining cells in each well was quantified using the 
cell viability indicator, resazurin. As seen in Figure 6.2b, activity was detected across many 
fractions in the peptide library. This result is unusual for plant extracts and suggests that the 
fractions may not have been desalted thoroughly. However, clear regions of activity are still 
apparent, across fractions 18-24, 25-30, and 31-36. This assay has been repeated for 
clarity/bioactivity confirmation (data not shown), and the region with the strongest activity 
(Figure 6.2b, fractions 27-29, highlighted in blue) was selected for downstream analysis. 
6.3.5 Reversed Phase Fractionation of Active SCX Fractions 
As the initial SCX peptide library displayed activity in an unusually large number of 
fractions, a second round of fractionation was used to further separate and probe individual 
regions of activity. As such, SCX fractions with the highest activity levels (27-29) were 
recombined and subject to reversed phase separation and fractionation. A 42-minute optimized 
run with a two-step organic gradient to elute retained compounds was implemented. The 
resulting 220 nm trace is shown in Figure 6.3a. A small, unretained peak from 2-3 minutes is still 
evident; however, the majority of compounds in the sample are being retained on the reversed 
phase column. A strikingly wide peak is apparent from 16-19 minutes, but all other peaks display 





tricolor RP peptide library, 1-minute fractions were collected across the run, dried down, and 
resuspended in 25 μL of LC-MS grade water. 
6.3.6 Bioactivity Screening: RP Peptide Library 
Reversed phase library fractions were subject to bioactivity screening vs. E. coli, as described 
above except in duplicate due to limited sample volume. As seen in Figure 6.3b, a single, strong 
bioactivity region is detected across fractions 16-19 (highlighted in blue), with maximum activity 
occurring in fraction 17 and decreasing on either side. The additional active fraction to the right 
of the maximum suggests peak tailing, which aligns with the trend in UV data across that time 
frame. Reversed phase separation has the potential to denature peptides through elimination of 
secondary and tertiary structure often crucial to activity. However, conservation of activity after 
reverse phase fractionation indicates stability of the target peptide and is an exciting feature of 
candidates for drug development. 
6.3.7 LC-MS and Statistical Analysis of Peptide Libraries 
Both SCX and RP A. tricolor peptide libraries (fractions 11-40 and 11-35, respectively) were 
subjected to LC-MS/MS analysis. Peptide ion data reveals 11,558 and 8,001 features in the SCX 
and RP data sets, respectively. As the reversed phase peptide library generated a more defined 
bioactivity profile, PepSAVIms statistical analysis was performed on this data set. Binning of 
mass spectrometry features to reduce compound redundancy condensed this data set to 4,070 
features, and further filtering for compounds with their maximum abundance within the 
bioactivity region revealed 119 features possibly contributing to the bioactivity. Penalized linear 
regression of these remaining features divulges the top 20 compounds most-likely contributing to 





top candidate, 568.95 m/z. This feature corresponds to a 1703.82 Da peptide that was detected in 
three charge states and elutes around 17 minutes in the reversed phase nanoLC gradient.  
6.4 Peptide Characterization 
Experiments to sequence target peptides in the top 20 compound list are underway. The 
primary target of interest, a 1703.82 Da peptide, was selected for tandem MS in the DDA 
workflow, but displays minimal fragmentation. Additional measures for characterization 
including targeted fragmentation with increased collision energy on the TripleTOF, and 
complementary HCD fragmentation using the Orbitrap HF-X are underway.  
Additionally, although A. tricolor has not been genome sequenced transcriptomic data is 
available as part of the oneKP initiative to generate large-scale gene sequencing data for 1000 
plant species20-23. This data has been used for in-house translation of a protein database that can 
facilitate a traditional bottom-up proteomics approach. As such, a reduction, alkylation, digestion 
(trypsin and Glu-C) workflow is being used to achieve high-quality MS/MS data to be searched 
against the A. tricolor protein database in Mascot. Initial reduction and alkylation mass shifts 
indicate the presence of one disulfide bond in the target peptide. No additional mass shifts of the 
target peptide are detected after subsequent Glu-C digestion, indicating the absence of glutamic 
acid and aspartic acid residues. Tryptic digestion eliminates the reduced peptide therefore 
indicating the presence of multiple basic residues within the target peptide. 
6.5 Bioactivity Characterization  
To further probe the activity of the A. tricolor peptide library, SCX fractions were screened 
against three of the ESKAPE pathogens: Staphylococcus aureus, Klebsiella pneumoniae, and 





vs. A. baumannii (Figure 6.5) which may be similar to the activity seen vs. E. coli. As such, this 
assay is being repeated with a higher concentration of peptide library for bioactivity assessment. 
Additionally, more material is being prepared to screen against the remaining three ESKAPE 
pathogens: E. faecalis, P. aeruginosa, and E. cloacae. 
6.6 Conclusion 
Using PepSAVI-MS, we begin to explore the antimicrobial activity from the aerial tissue of 
A. tricolor. Bioactivity results indicate strong activity against the gram-negative bacterium 
Escherichia coli, which is retained through both SCX and reversed phase fractionation. Using 
the PepSAVIms statistical analysis package, the top 20 candidates most-likely contributing to the 
observed bioactivity have been identified, and further work is being performed to identify the 
specific bioactive component. The purified bioactive peptide will undergo activity validation 
against E. coli and will be screened for activity against a full panel of gram-negative and gram-
positive bacteria to assess full bioactivity potential. This work represents the first novel peptide 
identified via PepSAVI-MS and showcases the potential of this pipeline for natural product 









Figure 6.1 Amaranthus tricolor plant growth at 2, 4, and 8 weeks after planting the seeds. The 




































Figure 6.5 A. tricolor SCX peptide library bioactivity against a subset of the ESKAPE pathogens 
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 Future Work and Conclusions 
7.1 Future Work 
7.1.1 High-Throughput Screening of Traditional Medicinal Plants 
High-throughput screening of traditional medicinal plants is continuously underway in the 
Hicks Laboratory. Plant species have been selected based on criteria including known biological 
activity, traditional use, and availability. To date, almost 70 botanical species have been grown 
and harvested with 51 crude extracts and 31 peptide libraries created for high-throughput 
screening of medicinal plant species. Peptide libraries will be screened against a panel of 
pathogen selected based on literature precedent. The most promising plant species will be 
identified and prioritized based on strength and breadth of activity. Prioritized species will be 
subject to LC-MS/MS and statistical analysis for determination of putative bioactive peptide 
targets. Selected peptides from the top 20 compound lists will undergo subsequent 
characterization and activity validation for novel bioactive peptide discovery.  
7.1.2 Induced Expression of Bioactive Peptides 
Although many bioactive peptides are constitutively expressed, expression of bioactive 
peptides can also be initiated or increased through biotic and abiotic stress conditions. 
Incorporation of induced bioactive peptides into the initial peptide library allows for access to 
peptides that might otherwise be unavailable. Abiotic stress conditions, including salt, wounding, 
and chemical stress, will be the initial focus of induced bioactive peptides due to ease of 
implementation. To introduce abiotic stress conditions, hydroponic and liquid culture growth 





Regardless of induction strategy, after the initial stress is applied plant material is harvested and 
taken through the PepSAVI-MS pipeline without any further modification. 
7.1.3 Validation Challenges 
The developed PepSAVI-MS pipeline rapidly identifies bioactive peptide targets that require 
sequence identification, structural characterization, and activity validation. Although 
prioritization of these compounds is a necessary first step, significant focus on peptide targets 
will be required to fully characterize a bioactive peptide. While these steps are beyond the scope 
of this dissertation, they are crucial to complete the bioactive peptide discovery process. As such, 
the remaining sections identify possible challenges and ideas to address them. 
7.1.4 Peptide Isolation/Synthesis 
Target peptides must be isolated or synthesized for activity validation and full structural 
characterization. The overall complexity of the peptide, accounting for primary sequence, 
secondary structure, and complexity of post-translational modifications, as well as the abundance 
of the target peptide produced by the natural product, will dictate the appropriate route forward 
for isolation. Isolation options include purification from the native plant species if sufficient 
material can be obtained1 and solid phase chemical synthesis2-4. To enable production of peptides 
and small proteins, Fmoc-based solid-phase peptide synthesis (SPPS) will be performed using a 
flow chemistry-based platform5-6. Using this proven instrument, peptide fragments are rapidly 
generated and further purified with modern chromatography methods. In order to access linear 
structures greater than 50 amino acids, peptide fragments are joined together using established in 
situ native-chemical ligation methodology, where the activated C-terminus of one peptide is 
chemoselectively joined with another peptide fragment containing an N-terminal Cys residue7. 





high dilution conditions8 or enzyme-mediated processes for backbone cyclization9. Towards the 
synthesis of disulfide-containing peptide targets, the wealth of prior experimentation will serve 
as guide, where careful consideration of buffer additives can facilitate improved folding10. Initial 
conditions to afford correct disulfide regiochemistry will include dilute iodine or DMSO as 
oxidants; however, use of thermodynamic folding conditions with thiol-based redox pairs such as 
GSH/GSSG may better mimic endogenous conditions8, 11. In cases where these oxidative folding 
methods fail, orthogonal S-Cys protection will be employed to engineer desired disulfide 
pairing12.  
7.1.5 MOA Determination 
Mechanisms of action (MOAs) of high priority peptides will be explored using a two-
pronged strategy. First, compounds will be assessed for common antibacterial MOAs, using the 
bacterial cytological profiling (BCP) method pioneered by the Pogliano group at the University 
of California San Diego13. BCP uses fluorescent microscopy to assess alterations in bacterial 
ultrastructure upon exposure to antibacterial agents. By comparison to the discrete and specific 
effects of known classes of antibacterial agents, one can begin to develop an understanding of 
novel drug MOA. This approach has been successful in identifying the MOA of a number of 
novel antibacterial agents13-19, including the identification of a novel class of bis-cyclic 
guanidines that affect bacteria via the inhibition of protein synthesis. Novel leads that meet 
progression criteria will first be assessed using BCP methodologies.  
A second, complimentary approach, employing CETSA (Cellular Thermal Shift Assays) will 
be used for compounds requiring further analysis20. CETSA works on the basis that ligands 
(drugs) bound to target proteins increase their stability; thus, when one applies heat to treated and 





observed for proteins bound by the compound in question. This approach has been used 
extensively in the context of eukaryotic drug discovery, particular in the area of oncology21-24.  
7.1.6 Translation  
Upon successful characterization of active peptide targets, strategies to improve in vivo 
stability and immunogenicity profiles will be investigated to assess translation potential. Such 
strategies include incorporation of D-amino acids, amino acid substitution with non-native 
peptide sidechains, N-methylation of peptide backbone, incorporation of peptoid or beta-amino 
acids, disulfide bond replacement, and peptide stapling25-28. As a final measure of effectivity for 
lead peptides, in vivo efficacy testing will be performed using lethal murine peritonitis models of 
infection, which have been extensively described in the context of drug discovery for each of the 
ESKAPE organisms29-34. 
7.2 Conclusions 
PepSAVI-MS is a powerful and versatile pipeline for natural product bioactive peptide 
discovery. Successful identification of cyO2 (Viola odorata), KP4 (Ustilago maydis), and Bac-
21 (Enterococcus faecalis) demonstrate proof-of-principle for the developed pipeline and 
establish its utility across source material from plants, fungi, and bacteria. PepSAVI-MS is easily 
adaptable to accommodate a variety of bioassay screens, including antibacterial, antifungal, and 
anticancer, in both liquid- and agar-based formats. After bioactivity screening, peptide libraries 
can be analyzed via LC-MS intact or digested (for genome sequenced organisms), further 
extending the utility of the pipeline to use with resolving power-limited mass spectrometers. The 
established pipeline is being applied for novel bioactive peptide discovery and has resulted in 





In comparison to current methods for targeted bioactive peptide discovery, PepSAVI-MS 
provides a direct measure of bioactivity while remaining high-throughput and requires no a 
priori knowledge of an organism’s genome or the biosynthetic pathways of known bioactive 
peptides. Combination of PepSAVI-MS with other peptidomics tools, including genome mining 
and molecular networking, have the possibility to greatly expand its capabilities when this 
information is available. PepSAVI-MS is uniquely poised probe natural product extracts with a 
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